Aytu BioPharma (AYTU) 10-Q 14 Nov 23 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	3 Months Ended
	Sep. 30, 2023	Nov. 01, 2023
Cover [Abstract]
Entity Central Index Key	0001385818
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-38247
Entity Registrant Name	AYTU BIOPHARMA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-0883144
Entity Address, Address Line One	7900 East Union Avenue
Entity Address, Address Line Two	Suite 920
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	437-6580
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Listing, Par Value Per Share	$ 0.0001
Trading Symbol	AYTU
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,567,490
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Current assets
Cash and cash equivalents	$ 19,964	$ 22,985
Accounts receivable, net	29,882	28,937
Inventories	12,966	11,995
Prepaid expenses	7,038	8,047
Other current assets	749	868
Total current assets	70,599	72,832
Property and equipment, net	1,722	1,815
Operating lease right-of-use asset	2,454	2,054
Intangible assets, net	57,341	58,970
Other non-current assets	772	792
Total non-current assets	62,289	63,631
Total assets	132,888	136,463
Current liabilities
Accounts payable and other	14,466	13,478
Accrued liabilities	40,730	46,799
Short-term line of credit	1,215	1,563
Current portion of debt	62	85
Other current liabilities	8,990	7,090
Total current liabilities	65,463	69,015
Debt, net of current portion	14,842	14,713
Derivative warrant liabilities	12,310	6,403
Other non-current liabilities	8,106	6,975
Total liabilities	100,721	97,106
Commitments and contingencies (Note 13)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding as of September 30, 2023 and June 30, 2023
Common Stock, par value $.0001; 200,000,000 shares authorized; 5,530,235 and 5,517,174 shares issued or outstanding, respectively, as of September 30, 2023 and June 30, 2023	1	1
Additional paid-in capital	344,415	343,485
Accumulated deficit	(312,249)	(304,129)
Total stockholders' equity	32,167	39,357
Total liabilities and stockholders' equity	$ 132,888	$ 136,463

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Preferred stock
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	5,530,235	5,517,174
Common stock, shares outstanding (in shares)	5,530,235	5,517,174

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Consolidated Statements of Operations
Product revenue, net	$ 22,099	$ 27,655
Revenue from Contract with Customer, Product and Service	Product	Product
Cost of sales	$ 7,315	$ 9,623
Gross profit	14,784	18,032
Operating expenses
Selling and marketing	7,422	10,102
General and administrative	6,956	7,322
Research and development	604	1,064
Amortization of intangible assets	1,306	1,197
Loss from contingent consideration		155
Total operating expenses	16,288	19,840
Loss from operations	(1,504)	(1,808)
Other income (expense)
Other expense, net	(709)	(1,084)
(Loss) gain on derivative warrant liabilities	(5,907)	2,191
Total other (expense) income	(6,616)	1,107
Loss before income tax	(8,120)	(701)
Net loss	$ (8,120)	$ (701)
Weighted average number of common shares outstanding - basic (in shares)	5,482,037	2,517,906
Weighted average number of common shares outstanding - diluted (in shares)	5,482,037	2,517,906
Basic net loss per common share (in dollars per share)	$ (1.48)	$ (0.28)
Diluted net loss per common share (in dollars per share)	$ (1.48)	$ (0.28)

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Beginning balance at Jun. 30, 2022		$ 331,386	$ (287,078)	$ 44,308
Beginning balance (in shares) at Jun. 30, 2022	1,928,941
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		1,177		1,177
Stock-based compensation (in shares)	(1,666)
Issuance of common stock, net of issuance costs		3,564		3,564
Issuance of common stock, net of issuance costs (in shares)	1,194,196
Net loss			(701)	(701)
Ending balance at Sep. 30, 2022		336,127	(287,779)	48,348
Ending balance (in shares) at Sep. 30, 2022	3,121,471
Beginning balance at Jun. 30, 2022		331,386	(287,078)	44,308
Beginning balance (in shares) at Jun. 30, 2022	1,928,941
Ending balance at Jun. 30, 2023	$ 1	343,485	(304,129)	$ 39,357
Ending balance (in shares) at Jun. 30, 2023	5,517,174			5,517,174
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		930		$ 930
Stock-based compensation (in shares)	13,061
Net loss			(8,120)	(8,120)
Ending balance at Sep. 30, 2023	$ 1	$ 344,415	$ (312,249)	$ 32,167
Ending balance (in shares) at Sep. 30, 2023	5,530,235			5,530,235

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net loss	$ (8,120)	$ (701)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation, amortization and accretion	2,230	2,301
Stock-based compensation expense	930	1,177
Loss (gain) on derivative warrant liabilities	5,907	(2,191)
Amortization of senior debt discount	148	145
Loss from contingent consideration		155
Inventory write-down	51	82
Other noncash adjustments	(6)	(33)
Changes in operating assets and liabilities:
Accounts receivable	(945)	(6,212)
Inventories	(1,023)	(2,104)
Prepaid expenses and other current assets	1,125	(1,801)
Accounts payable and other	914	3,587
Accrued liabilities	(5,166)	(3,481)
Other operating assets and liabilities, net	3,744	(72)
Net cash used in operating activities	(211)	(9,148)
Investing Activities
Other investing activities	(76)	42
Net cash (used in) provided by investing activities	(76)	42
Financing Activities
Proceeds from issuance of stock and warrants		10,416
Net (payments made on) proceeds received from, short-term line of credit	(348)	4,274
Payment made to fixed payment arrangement	(2,204)	(301)
Payment of stock issuance costs	(160)	(793)
Payments made to borrowings	(22)	(26)
Other financing activities		(13)
Net cash (used in) provided by financing activities	(2,734)	13,557
Net change in cash and cash equivalents	(3,021)	4,451
Cash and cash equivalents at beginning of period	22,985	19,360
Cash and cash equivalents at end of period	19,964	23,811
Supplemental cash flow data
Cash paid for interest	$ 1,359	565
Non-cash investing and financing activities:
Fair value of warrants at issuance, net		5,953
Other noncash investing and financing activities		$ 146

Nature of Business, Financial C

Nature of Business, Financial Condition, Basis of Presentation	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business, Financial Condition, Basis of Presentation	1. Nature of Business, Financial Condition, Basis of Presentation Aytu BioPharma, Inc. (“Aytu”, the “Company” or “we”), is a pharmaceutical company focused on commercializing novel therapeutics and consumer health products. The Company operates through two business segments (i) the Rx Segment, consisting of prescription pharmaceutical products and (ii) the Consumer Health Segment, which consists of various consumer healthcare products (the “Consumer Health Portfolio”). The Company was originally incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado and was re-incorporated as Aytu BioScience, Inc in the state of Delaware on June 8, 2015. Following the acquisition of Neos Therapeutics, Inc. (“Neos”) in March 2021, (the “Neos Acquisition”) the Company changed its name to Aytu BioPharma, Inc. On January 6, 2023, the Company effected a reverse stock split in which each common stockholder received one share of common stock for every twenty The Rx Segment primarily consists of two product portfolios: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (“ADHD”) together the “ADHD Portfolio”, and the “Pediatric Portfolio” consisting of Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency, and Karbinal ER, an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions. The Consumer Health Portfolio consists of multiple consumer health products competing in large healthcare categories, including allergy, hair regrowth, diabetes support, digestive health, sexual and urological health and general wellness, commercialized through direct mail and e-commerce marketing channels. To date, the Consumer Health Segment has generated negative cash flows. In the fiscal 2023 year, the Company announced it would wind down or monetize the Consumer Health Segment in the fiscal 2024 year. The Company’s strategy is to continue building its portfolio of revenue-generating prescription pharmaceutical products, leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. As a result of focusing on building the portfolio of revenue-generating products and generating profitability, in the fiscal 2023 year, the Company indefinitely suspended active development of its clinical development programs including AR101 (enzastaurin), and terminated the license agreements relating to Healight and NT0502 (N-desethyloxybutynin). As of September 30, 2023, the Company had $20.0 million of cash and cash equivalents and $29.9 million in accounts receivable. The Company’s operations have historically consumed cash and may continue to consume cash in the future. The Company incurred a net loss of $8.1 million and $0.7 million during the three months ended September 30, 2023 and 2022, respectively. The Company had an accumulated deficit of $312.2 million and $304.1 million as of September 30, 2023 and June 30, 2023, respectively. Cash used in operations was $0.2 million and $9.1 million during the three months ended September 30, 2023 and 2022, respectively. In addition, the Company has non-operating liabilities that are scheduled to, or may become, current in the fifteen months following the filing of this Quarterly Report on Form 10-Q, most notably the maturity of the $15 million Avenue Capital term note (the “Avenue Note”, see Note 11 – Long-term Debt). The Company expects to refinance the Avenue Note in the event it does not have sufficient cash on hand to retire it at maturity. As a result of this, there exists substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include adjustments that might be necessary if the Company is unable to continue as a going concern. Management plans to mitigate the conditions that raise substantial doubt about its ability to continue as a going concern are primarily focused on (i) improving cash flows from operations, (ii) winding down or monetizing the Consumer Health Segment, (iii) refinancing its $15 million Avenue Note to extend its maturity date, and, (iv) , if necessary, raising additional capital through public or private equity, debt offerings, or monetizing additional assets in order to meet its obligations. Management believes that the Company has access to capital resources, however, the Company cannot provide any assurance that it will be able to raise additional capital, monetize assets, or obtain new financing on commercially acceptable terms. If the Company is unable to support its operations and obligations, it may be required to curtail its operations, or delay the execution of its business plan. Alternatively, any efforts by the Company to reduce its expenses may adversely impact its ability to sustain revenue-generating activities or otherwise operate its business. As a result, there can be no assurance that the Company will be successful in implementing its plans to alleviate this substantial doubt about its ability to continue as a going concern. Basis of Presentation. Prior Period Reclassification

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Significant Accounting Policies	2. Significant Accounting Policies Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. ​ Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable. Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2023. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a limitation on its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability. Employee Retention Credit On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020 through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. In accordance with IAS 20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall either be recorded as an offset against payroll costs or recognized as other income in the consolidated statement of operations (see Note – 9 Other Liabilities). Recent Adopted Accounting Pronouncements Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” 15, 2022. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal year ended June 30, 2024. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements. For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. Other than the application of IAS 20 for the Employee Retention Credit, there have been no significant changes to the Company’s significant accounting policies during the three months ended September 30, 2023.

Revenues from Contracts with Cu

Revenues from Contracts with Customers	3 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenues from Contracts with Customers	3. Revenues from Contracts with Customers Net product sales in the Rx Segment consist of sales of prescription pharmaceutical products, principally to a limited number of wholesale distributors and pharmacies in the United States. Rx product revenue is recognized at the point in time that control of the product transfers to the customer, which typically aligns with shipping terms (i.e., upon delivery), generally “free-on-board” destination when shipped domestically within the United States, and “free-on-board” shipping point when shipped internationally, consistent with contractual terms. The Company generates Consumer Health Segment revenue from sales of various consumer health products through e-commerce platforms and direct-to-consumer marketing channels. Revenue is generally recognized “free-on-board” shipping point, consistent with contractual terms and aligning with the transfer of control of the products. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction that are collected by the Company from customers are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost, and are included in cost of sales. ​ Savings offers, rebates, and wholesaler chargebacks ​ Revenues by Segment. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ 2023 2022 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ Rx Segment ​ $ 17,817 ​ $ 18,652 Consumer Health Segment ​ 4,282 ​ 9,003 Total consolidated revenue ​ $ 22,099 ​ $ 27,655 ​ Revenues by Product Portfolio. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ ​ 2023 2022 ​ ​ (In thousands) Rx Segment: ​ ​ ​ ​ ​ ​ ADHD Portfolio ​ $ 15,128 ​ $ 11,585 Pediatric Portfolio ​ ​ 2,565 ​ ​ 6,558 Other ​ ​ 124 ​ ​ 509 Total Rx Segment revenue ​ $ 17,817 ​ $ 18,652 ​ Other includes discontinued and deprioritized products in the Rx Segment. The Consumer Health Segment is comprised of one product portfolio, the Consumer Health Portfolio. ​ Revenues by Geographic location.

Inventories

Inventories	3 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consist of raw materials, work in process and finished goods, and are recorded at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company periodically reviews the composition of its inventories to identify obsolete, slow-moving or otherwise unsaleable items. In the event that such items are identified and there are no alternate uses for the inventory, the Company will record a charge to reduce the value of the inventory to net realizable value in the period first recognized. The Company incurred $0.1 million in inventory write-downs for each of the three months ended September 30, 2023 and 2022. Inventory balances consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ (In thousands) Raw materials $ 1,968 $ 1,301 Work in process ​ ​ 3,288 ​ ​ 2,956 Finished goods ​ 7,710 ​ 7,738 Inventories ​ $ 12,966 ​ $ 11,995

Property and Equipment

Property and Equipment	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Properties and equipment are recorded at cost and depreciated on a straight-line basis over the assets’ estimated economic life. Leasehold improvements are amortized over the shorter of the estimated economic life or remaining lease term. Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,433 $ 2,433 Leasehold improvements 999 ​ 999 Office equipment, furniture and other 1,125 ​ 1,125 Lab equipment 832 ​ 832 Assets under construction ​ ​ 323 ​ ​ 107 Property and equipment, gross ​ ​ 5,712 ​ ​ 5,496 Less accumulated depreciation and amortization ​ ​ (3,990) ​ ​ (3,681) Property and equipment, net $ 1,722 ​ $ 1,815 ​ Depreciation and amortization expense from property and equipment was $0.3 million for each of the three months ended September 30, 2023 and 2022.

Leases

Leases	3 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Leases	6. Leases The Company has entered into various operating lease agreements for certain of its offices, manufacturing facilities and equipment, and finance lease agreements for certain equipment. These leases have original lease periods expiring between fiscal years 2024 and 2029. Most leases include one or more options to renew, and the exercise of a lease renewal option typically occurs at the discretion of both parties. Certain leases also include options to purchase the leased property. The Company’s lease agreements generally do not contain any material residual value guarantees or material restrictive covenants. In May 2023, the Company entered into a lease agreement to relocate its principal office. The space was made available to the Company in September 2023 (lease commencement) with an initial term of five The components of lease expenses are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ ​ September 30, ​ ​ ​ 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 360 ​ $ 222 Operating expenses Short-term lease cost 23 ​ 160 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of leased assets 14 ​ 18 Cost of sales Interest on lease liabilities ​ ​ 1 ​ ​ 3 ​ Other expense, net Total net lease cost $ 398 ​ $ 403 ​ Supplemental balance sheet information related to leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2023 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets * ​ $ 2,454 ​ $ 2,054 Operating lease right-of-use asset Finance lease assets ​ ​ — ​ 159 Property and equipment, net Total leased assets ​ $ 2,454 ​ $ 2,213 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,265 ​ $ 1,258 ​ Other current liabilities Finance leases ​ ​ 62 ​ ​ 85 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1,208 ​ ​ 832 ​ Other non-current liabilities Total lease liabilities ​ $ 2,535 ​ $ 2,175 ​ ​ ​ * Includes $0.2 million from the Consumer Health Segment as of September 30, 2023 and June 30, 2023. ​ Remaining lease term and discount rate used are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.65 ​ ​ 1.72 ​ Finance lease assets ​ 0.62 ​ ​ 0.87 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 8.60 % ​ 7.78 % Finance lease assets ​ ​ 6.54 % ​ 6.54 % ​ Supplemental cash flow information related to lease is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 360 ​ $ 357 Operating cash flows from finance leases ​ $ 1 ​ $ 3 Financing cash flows from finance leases ​ $ 23 ​ $ 27 ​ As of September 30, 2023, the maturities of the Company’s future minimum lease payments were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 (remaining 9 months) ​ $ 1,035 ​ $ 64 2025 ​ ​ 937 ​ ​ — 2026 ​ ​ 282 ​ ​ — 2027 ​ ​ 241 ​ ​ — 2028 ​ ​ 199 ​ ​ — Thereafter ​ ​ 168 ​ ​ — Total lease payments ​ ​ 2,862 ​ ​ 64 Less: Imputed interest ​ ​ (389) ​ ​ (2) Lease liabilities ​ $ 2,473 ​ $ 62

Intangible Assets

Intangible Assets	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	7. Intangible Assets The Company’s strategy is to continue building its portfolio of revenue-generating products by leveraging its commercial team’s expertise to build leading brands within large therapeutic markets. The following table provides the summary of the Company’s intangible assets as of September 30, 2023 and June 30, 2023, respectively. Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (11,683) ​ $ — ​ $ 30,493 11.29 Acquired technology right ​ ​ 30,200 ​ ​ (4,498) ​ ​ — ​ ​ 25,702 ​ 14.50 Acquired product distribution rights ​ 6,207 ​ (5,061) ​ — ​ 1,146 0.75 Total ​ $ 78,583 ​ $ (21,242) ​ $ — ​ $ 57,341 12.52 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67 ​ The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter: ​ ​ ​ ​ ​ ​ September 30, ​ ​ (In thousands) 2024 (remaining 9 months) ​ $ 4,889 2025 ​ ​ 4,989 2026 ​ ​ 4,989 2027 ​ ​ 4,989 2028 ​ ​ 4,988 Thereafter ​ ​ 32,497 Total future amortization expense ​ $ 57,341 ​ Acquired Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. Karbinal ER. Poly-Vi-Flor and Tri-Vi-Flor. ADHD Portfolio. Acquired Technology Right TRRP Technology. Acquired Product Distribution Rights (and customer list) In connection with the Innovus Acquisition, the Company obtained 35 products with a combination of over 300 registered trademarks and/or patent rights and customer lists. The customer lists are fully amortized. As of June 30, 2023, the acquired product distribution rights included an impairment charge of $3.0 million due to the discontinuance of products in the Consumer Health Segment. Acquired In-Process R&D IPR&D – NT0502. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.6 million and $1.5 million for the three months ended September 30, 2023 and 2022, respectively.

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Sep. 30, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	8. Accrued liabilities Accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Accrued savings offers ​ $ 13,023 ​ $ 15,739 Accrued program liabilities ​ ​ 9,994 ​ ​ 11,012 Accrued employee compensation ​ ​ 5,374 ​ ​ 5,675 Accrued customer and product related fees ​ ​ 4,691 ​ ​ 6,579 Return reserve ​ 5,137 ​ 5,777 Other accrued liabilities ​ ​ 2,511 ​ ​ 2,017 Total accrued liabilities ​ $ 40,730 ​ $ 46,799 ​ Savings offers represent programs for the Company’s patients covered under commercial payor plans in which the cost of a prescription to such patients is discounted. ​ Program liabilities include government and commercial rebates. ​ Accrued employee compensation includes sales commissions, vacation earned, and accrued payroll. ​ Customer and product related fees include accrued expenses and deductions for rebates, wholesaler chargebacks and fees, and other product-related fees and deductions such as royalties for Pediatric Portfolio products, accrued distributor fees, and Medicaid liabilities. ​ Other accrued liabilities consist of accrued license fees, legal settlements, professional fees, credit card liabilities, taxes payable, and samples expense; none of which individually represent greater than five percent of total liabilities.

Other Liabilities

Other Liabilities	3 Months Ended
	Sep. 30, 2023
Other Liabilities Disclosure [Abstract]
Other Liabilities	9. Other Liabilities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Fixed payment arrangements ​ $ 9,380 ​ $ 10,420 Operating lease liabilities ​ 2,473 ​ 2,090 Employee retention credit ​ ​ 3,759 ​ ​ — Other ​ ​ 1,484 ​ ​ 1,555 Total other liabilities ​ ​ 17,096 ​ ​ 14,065 Less: current portion ​ ​ (8,990) ​ ​ (7,090) Total other liabilities, non-current ​ $ 8,106 ​ $ 6,975 ​ Fixed Payment Arrangements. Fixed payment arrangements represent obligations to an investor assumed as part of the acquisition of products from Cerecor, Inc. in 2019, including fixed and variable payments. These obligations included fixed monthly payments equal to $0.1 million from November 2019 through January 2021, plus $15.0 million due in January 2021, of which $15.0 million was paid down early in May 2020. Monthly variable payments due to the same investor are equal to 15.0% of net revenue generated from a subset of the Pediatric Portfolio, subject to an aggregate monthly minimum of $0.1 million, except for January 2021, when a one-time payment of $0.2 million was due and paid. The variable payment obligation was to continue until the earlier of (i) aggregate variable payments of approximately $9.3 million have been made or (ii) February 12, 2026. On June 21, 2021, the Company entered into a Waiver, Release and Consent pursuant to which the Company paid $2.8 million to the investor in partial satisfaction of the fixed obligation. The Company agreed to pay the remaining fixed obligation of $3.0 million in six equal quarterly payments of $0.5 million each over six quarters beginning September 30, 2021. The Company accounted for the Waiver, Release and Consent as a debt, and remeasured the related liabilities using a discounted cash flow model. This fixed payment arrangement was paid in full by January 2023. ​ The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. As of September 30, 2023, the fixed payment arrangement balance was $1.8 million in other current liabilities, and $1.7 million in other non-current liabilities on the consolidated balance sheet. ​ On May 12, 2022, the Company entered into an agreement with Tris to terminate the Tuzistra XR License, Development, Manufacturing and Supply Agreement dated November 2, 2018 (the “License Agreement”). Pursuant to such termination, the Company agreed to pay Tris a total of approximately $9.0 million, which reduced its total liability for minimum payments by approximately $8.0 million from the original License Agreement. As of September 30, 2023, the balance was $6.0 million in other current liabilities on the consolidated balance sheet. Employee Retention Credit. The Employee Retention Credit (“ERC”) in other non-current liabilities was a result of $3.8 million in proceeds the Company received from the ERC program during the quarter ended September 30, 2023. The ERC is a refundable payroll tax credit from the Coronavirus Aid, Relief, and Economic Security Act enacted by the U.S. government to provide certain relief from the COVID-19 pandemic. The refundable payroll tax credit shall be recognized in the consolidated statement of operations following any adjustments from its regulatory audit or upon further clarifications from the Internal Revenue Service (see Note 2 – Significant Accounting Policies). The associated vendor fee of $0.4 million was expensed as incurred in the quarter ended September 30, 2023. Other. Other consists of taxes payable and deferred cost related to the Company’s technology transfer.

Line of Credit

Line of Credit	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Line of Credit	10. Line of Credit Upon closing of the Neos Acquisition in March 2021, the Company assumed obligations under the secured credit agreement that Neos had entered into with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”) as agent for the lenders (the “Eclipse Loan Agreement”). Under the Eclipse Loan Agreement, Eclipse extended up to $25.0 million in secured revolving loans to Neos (the “Revolving Loans”), of which up to $2.5 million was available for short-term swingline loans against 85% of eligible accounts receivable. The Revolving Loans thereunder, accrued at variable interest through maturity at the one-month Secure Overnight Financing Rate (“SOFR”), plus 4.50%. The Eclipse Loan Agreement included an unused line fee of 0.50% of the average unused portion of the maximum revolving facility amount during the immediately preceding month. Interest is payable monthly in arrears. The original maturity date under the Eclipse Loan Agreement was May 11, 2022. In connection with the Avenue Capital Agreement, described in Note 11— Long-term Debt, the Company entered into a Consent, Waiver and Second Amendment to Eclipse Loan Agreement, dated as of January 26, 2022 (together, the “Eclipse Second Amendment”). Pursuant to the Eclipse Second Amendment, Eclipse (i) consented to Aytu and certain of its subsidiaries joining as obligors to the Revolving Loans provided by the Eclipse Loan Agreement, (ii) consented to the Company entering into the Avenue Capital Agreement, (iii) extended the maturity date of the Eclipse Loan Agreement to January 26, 2025, (iv) removed the requirement for the Company to comply with the ongoing fixed charge coverage ratio financial covenant applicable to the borrowers under the Eclipse Loan Agreement, (v) consented to the first priority lien granted by Aytu in favor of the Avenue Capital Agent, (vi) reduced the maximum availability under the Revolving Loans from $25.0 million to $12.5 million minus a $3.5 million availability block, (vii) increased the availability block from $1.0 million to $3.5 million, (viii) consented to the full repayment under the Deerfield Facility, defined below, and (ix) made certain other modifications to conform to the Avenue Capital Agreement and to reflect the consummation of the transactions thereof, in each case subject to the terms and conditions of the Eclipse Second Amendment. On March 24, 2023, the Company and certain of its subsidiaries entered into an Amendment No. 4 (the “Eclipse Fourth Amendment”) to the Eclipse Loan Agreement. The Eclipse Fourth Amendment, among other things, provided for an aggregate increase of $2.0 million to Eclipse commitment to make revolving loans from time to time under the Eclipse Loan Agreement, and increased the maximum amount available under the revolving credit facility provided under the Eclipse Loan Agreement to $14.5 million. The ability to make borrowings and obtain advances of revolving loans under the Eclipse Loan Agreement remains subject to a borrowing base and reserve, and availability blockage requirements. In the event that, for any reason, all or any portion of the Eclipse Loan Agreement is terminated prior to the scheduled maturity date, in addition to the payment of all outstanding principal and unpaid accrued interest, the Company is required to pay a fee equal to (i) 2.0% of the Revolving Loans commitment if such event occurs on or before January 26, 2023, (ii) 1.0% of the Revolving Loans commitment if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 0.5% of the Revolving Loans commitment if such event occurs after January 26, 2024 but on or before January 26, 2025. The Company may permanently terminate the Eclipse Loan Agreement at any time with at least five business days prior notice to Eclipse. The Eclipse Loan Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restrict the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of Eclipse. A failure to comply with these covenants could permit Eclipse to declare the Company’s obligations under the Eclipse Loan Agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2023, the Company was in compliance with the covenants under the Eclipse Loan Agreement, as amended. The Company’s obligations under the Eclipse Loan Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of Eclipse on the ABL Priority Collateral, and a second priority lien in favor of Eclipse on the Term Loan Priority Collateral, as each is defined in the Replacement Term Loan Intercreditor Agreement, as defined in the Eclipse Loan Agreement, as amended by the Eclipse Second Amendment. Total interest expense on the Revolving Loans, including amortization of deferred financing costs, was $27,000 and ​

Long-term Debt

Long-term Debt	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Long-term Debt	11. Long-term Debt Avenue Capital Loan. On January 26, 2022 (“Closing Date”), the Company entered into a Loan and Security Agreement (the “Avenue Capital Agreement”) with Avenue Venture Opportunities Fund, L.P. (“Avenue”) and Avenue Venture Opportunities Fund II, L.P. (Avenue 2”) as lenders (the “Avenue Capital Lenders”), and Avenue Capital Management II, L.P. as administrative agent (the “Avenue Capital Agent”, and collectively with the Avenue Capital Lenders, “Avenue Capital”), pursuant to which the Avenue Capital Lenders provided the Company and certain of its subsidiaries with a secured $15.0 million loan. The interest rate on the loan is the greater of the prime rate and 3.25%, plus 7.4%, payable monthly in arrears. The maturity date of the loan is January 26, 2025. The proceeds from the Avenue Capital Agreement were used to repay the Deerfield Facility. Pursuant to the Avenue Capital Agreement, the Company will make interest only payments for the first 18 months following the Closing Date (“Interest-only Period”). The Interest-only Period could be extended automatically without any action by any party for six months provided, as of the last day of the Interest-only Period then in effect, the Company received, prior to June 15, 2023, a specified amount of net proceeds from the sale and issuance of its equity securities (“Interest-only Milestone 1”). The Interest-only Period could further be extended automatically without any action by any party for an additional twelve months provided, the Company has achieved, prior to December 31, 2023, (i) Interest-only Milestone 1 and (ii) a specified amount of trailing 12 months revenue (“Interest-only Milestone 2”) as of the date of determination. In connection with the Eclipse Fourth Amendment, on March 24, 2023, Avenue and the Company entered into a First Amendment (the “Avenue Amendment”) to the Avenue Capital Agreement. The Avenue Amendment, among other things, permitted the increase in revolving loan commitment provided by the Eclipse Lender under the Eclipse Facility. In the event the Company prepays the outstanding principal prior to the maturity date, the Company will pay Avenue Capital a fee equal to (i) 3.0% of the loan if such event occurs on or before January 26, 2023, (ii) 2.0% of the loan if such event occurs after January 26, 2023 but on or before January 26, 2024, and (iii) 1.0% of the loan if such event occurs after January 26, 2024 but before January 26, 2025. In addition, upon the payment in full of the obligations, the Company shall pay to Avenue Capital a fee in the amount of $0.6 million (“Final Payment”). The Company accounted for the Final Payment as additional obligations on the debt, with the corresponding charge being recorded as debt discount. The Company’s obligations under Avenue Capital Agreement are secured by substantially all of the Company’s assets, with a first priority lien in favor of the Avenue Capital Agent on the Term Loan Priority Collateral, and a second priority lien in favor of the Avenue Capital Agent on the ABL Priority Collateral, as each is defined in the Intercreditor Agreement, as defined in the Avenue Capital Agreement. The Avenue Capital Agreement contains customary affirmative covenants, negative covenants and events of default, as defined in the agreement, including covenants and restrictions that, among other things, require the Company to satisfy certain capital expenditure limitations and other financial covenants, and restricts the Company’s ability to incur liens, incur additional indebtedness, make certain dividends and distributions with respect to equity securities, engage in mergers and acquisitions or make asset sales without the prior written consent of the Avenue Capital Lenders. A failure to comply with these covenants could permit the Avenue Capital Lenders to declare the Company’s obligations under the agreement, together with accrued interest and fees, to be immediately due and payable, plus any applicable additional amounts relating to a prepayment or termination, as described above. As of September 30, 2023, the Company was in compliance with the covenants under the Avenue Capital Agreement. On January 26, 2022 (“Issuance Date”), as consideration for entering into the Avenue Capital Agreement, the Company issued warrants to the Avenue Capital Lenders to purchase shares of common stock at an exercise price equal to $24.20 per share (the “Avenue Capital Warrants”). The Avenue Capital Warrants provided that in the event the Company were to engage in an equity offering at a price lower than $24.20 prior to June 30, 2022, the exercise price would be adjusted to the effective price of such equity offering, and the number of shares of common stock to be issued under the Avenue Capital Warrants would be adjusted as set forth in the agreement. The Avenue Capital Warrants are immediately exercisable and expire on January 31, 2027. The Company accounted for the Avenue Capital Warrants as a liability as the number of warrants was not fixed at the Issuance Date. The fair value of the Avenue Capital Warrants at issuance was approximately $0.6 million. On March 7, 2022, the Company closed on an equity offering of shares of common stock and warrants at an offering price of $25.00 per share. As this offering precluded the Company from pursuing any equity financing prior to July 7, 2022, and the effective price of the March 7, 2022 offering was more than the exercise price of the Avenue Capital Warrants, the number of shares of common stock issuable upon exercise of the Avenue Capital Warrants were set to 43,388 at an exercise price of $24.20. On October 25, 2022, the Company entered into an agreement with Avenue to extend the interest-only period of its existing senior secure loan facility held with Avenue. The amendment to the original loan agreement, which was executed in January 2022, extends the interest-only period to January of 2024. In exchange for this extension of the interest-only period, the Company and Avenue agreed to reset the exercise price of the warrants issued in conjunction with the original loan agreement to $8.60, corresponding to the warrant exercise price associated with the Company’s August 2022 equity financing. On June 13, 2023, in conjunction with the Securities Purchase Agreement described in Note 16 – Warrants, the interest-only period of the Avenue Capital Agreement was extended further, to January 26, 2025, upon the achievement of both the revenue-based milestone and equity raise-based milestone stipulated in the Avenue Capital Agreement. In addition to the debt discount discussed above, the Company incurred $0.4 million in loan origination, legal and other fees. The debt discount and issuance costs are being amortized over the term of the loan, using the effective interest method resulting in an effective rate of 19.6%. Total interest expense, including debt discount amortization, was $0.7 million and $0.6 million for the three months ended September 30, 2023 and 2022, respectively. Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2023 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (796) Financing leases, maturing through May 2024 ​ ​ 62 Total debt ​ ​ 14,904 Less: current portion ​ ​ (62) Non-current portion of debt ​ $ 14,842 ​ Future principal payments of long-term debt, including financing leases, are as follows: ​ ​ ​ ​ ​ ​ September 30, ​ ​ (In thousands) 2024 ​ $ 62 2025 ​ ​ 15,638 Future principal payments ​ ​ 15,700 Less unamortized discount and issuance costs ​ ​ (796) Less current portion ​ ​ (62) Non-current portion of debt ​ $ 14,842

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Considerations	12. Fair Value Considerations We determine the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to determine fair value as follows: ● Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; ● Level 2: Inputs that include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and ● Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, derivative warrant liabilities, fixed payment arrangements, and short-term and long-term debt. The carrying amounts of certain short-term financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. Short-term and long-term debt are reported at their amortized costs on our consolidated balance sheets. The remaining financial instruments and derivative warrant liabilities are reported on our consolidated balance sheets at amounts that approximate current fair values. The Company’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. There were no transfers between Level 1, Level 2, and Level 3 in the periods presented. Recurring Fair Value Measurements The following table presents the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2023 and June 30, 2023, by level within the fair value hierarchy. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at September 30, 2023 ​ Fair Value at September 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ ​ 12,310 ​ — ​ — ​ 12,310 Total ​ $ 12,310 $ — $ — ​ $ 12,310 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2023 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ ​ 6,403 ​ ​ — ​ ​ — ​ ​ 6,403 Total ​ $ 6,403 $ — $ — ​ $ 6,403 ​ Summary of Level 3 Input Changes The following table sets forth a summary of changes to those fair value measures using Level 3 inputs for the three months ended September 30, 2023. ​ ​ ​ ​ ​ ​ Derivative ​ ​ Warrant Liabilities ​ ​ (In thousands) Balance as of June 30, 2023 $ 6,403 Included in earnings ​ 5,907 Balance as of September 30, 2023 $ 12,310 ​ ​ Significant Assumptions The following table presents the valuation methodologies and key assumptions used for the marked to market fair value measurements of derivative warrant liabilities as of September 30, 2023. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 2023 Warrants ​ Warrants ​ Tranche A & B Other * Valuation methodology ​ Monte Carlo Simulation ​ ​ ​ ​ ​ ​ & Black-Scholes ​ ​ Black-Scholes ​ Equivalent term (years) ​ 4.69 ​ ​ 3.34-3.94 ​ Expected volatility 93.32 % 93.32 % Risk-free rate ​ 4.63 % ​ 4.70-4.78 % Dividend yield ​ 0.00 % ​ 0.00 % ​ ​ ​ ​ ​ ​ ​ * Includes August 2022 Warrants, March 2022 Warrants, and Avenue Capital Warrants. ​ The Black-Scholes option pricing model is used to value all warrants with significant Level 3 inputs. The Monte Carlo Simulation is used to simulate the exit price and EBITDA forecast; average warrant value per share is from 100,000 Monte Carlo simulations. The Monte Carlo is based on significant inputs including financial projections provided by the Company’s management used primarily to forecast future results not observable in the market, and thus, represents a Level 3 measure.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Pediatric Portfolio Fixed Payments and Product Milestone The Tris Karbinal Agreement grants the Company exclusive right to distribute and sell the product in the United States. The initial term of the agreement was 20 years. The Company will pay Tris a royalty equal to 23.5% of net sales. The Tris Karbinal Agreement also contains minimum unit sales commitments, which is based on a commercial year that spans from August 1 through July 31, of 70,000 units annually through 2025. The Company is required to pay Tris a royalty make whole payment of $30 for each unit under the 70,000-unit annual minimum sales commitment through 2025. The Tris Karbinal Agreement make-whole payment is capped at $2.1 million each year. The annual payment is due in August of each year. The Tris Karbinal Agreement also has multiple commercial milestone obligations that aggregate up to $3.0 million based on cumulative net sales, the first of which is triggered at $40.0 million of net revenues. Rumpus Earn Out Payments On April 12, 2021, the Company acquired substantially all of the assets of Rumpus, pursuant to which the Company acquired certain rights and other assets, including key commercial global licenses with Denovo Biopharma LLC (“Denovo”) and Johns Hopkins University (“JHU”), relating to AR101. Upon the achievement of certain regulatory and commercial milestones, up to $67.5 million in earn-out payments, which are payable in cash or shares of common stock, generally at the Company’s option, are payable to Rumpus. Under the license agreement with Denovo, the Company made a payment of $0.6 million for a license fee in April 2022. In addition, upon the achievement of regulatory and commercial milestones, the Company may be required to pay up to $101.7 million and escalating royalties based on net product sales ranging in percentage from the low teens to the high teens. Finally, under the license agreement with Johns Hopkins, the Company assumed the responsibility for royalties of 3.0% of net product sales, with a minimum of $20,000 per year, and upon the achievement of certain regulatory and commercial milestones, up to $1.6 million. In October 2022, the Company announced the indefinite suspension of its development of AR101. Product Contingent Liability In February 2015, Innovus acquired Novalere, which included the rights associated with distributing FlutiCare. As part of the Merger, Innovus is obligated to make five additional payments of $0.5 million when certain levels of FlutiCare sales are achieved. In fiscal year 2023, the manufacturer associated with this contingent liability filed for bankruptcy. There were no payments required in fiscal 2023, and we expect no payments to be made to Novalere. Legal Matters Witmer Class-Action Securities Litigation. Sabby Litigation. Stein Litigation.

Capital Structure

Capital Structure	3 Months Ended
	Sep. 30, 2023
Equity [Abstract]
Capital Structure	14. Capital Structure The Company has 200 million shares of common stock authorized with a par value of $0.0001 per share and 50 million shares of preferred stock authorized with a par value of $0.0001 per share. As of September 30, 2023 and June 30, 2023, the Company had 5,530,235 and 5,517,174 shares of common stock outstanding, respectively, and zero preferred shares outstanding, respectively. Included in the common stock outstanding are 46,656 shares of unvested restricted stock issued to executives, directors and employees. On June 8, 2020, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on June 17, 2020. This shelf registration statement covered the offering, issuance, and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2020 Shelf”). On June 4, 2021, the Company entered into a sales agreement with a sales agent, to provide for the offering, issuance and sale by the Company of up to $30.0 million of its common stock from time to time in “at-the-market” offerings under the 2020 Shelf (the “ATM Sales Agreement”). During the fiscal year ended June 30, 2023, the Company issued 699,929 shares of common stock under the ATM Sales Agreement, with total net proceeds of approximately $2.9 million. The 2020 Shelf expired in June 2023. On September 28, 2021, the Company filed a shelf registration statement on Form S-3, which was declared effective by the SEC on October 7, 2021. This shelf registration statement covered the offering, issuance and sale by the Company of up to an aggregate of $100.0 million of its common stock, preferred stock, debt securities, warrants, rights and units (the “2021 Shelf”). As of September 30, 2023, approximately $82.4 million remained available under the 2021 Shelf. This availability is subject to SEC 1.B.6 limitation to the Form S-3. On August 11, 2022, the Company closed on an underwritten public offering (the “August 2022 Offering”) utilizing the 2021 Shelf, pursuant to which it sold an aggregate of (i) 1,075,290 shares of its common stock, (ii) and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 87,500 shares of its common stock, and (iii) accompanying warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The combined public offering price for each share of common stock and accompanying common warrant was $8.60, and the combined offering price for each pre-funded warrant and accompanying common warrant was $8.58, which equated to the public offering price per share of the common stock and accompanying common warrant, less the $0.001 per share exercise price of each pre-funded warrant. The pre-funded warrants were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The Company raised $10.0 million in gross proceeds through the August 2022 Offering before underwriting fees and other expenses of $0.9 million. The pre-funded and common warrants have a combined fair value of approximately $6.0 million at issuance and are classified as derivative warrant liabilities, with the offset in additional paid in capital in stockholders’ equity in the Company’s consolidated financial statements (See Note 16 – Warrants). On June 8, 2023, using a placement agency, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock (the “Pre-Funded Warrants”), (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering (the Tranche B Warrants together with the Tranche A Warrants, the “Common Warrants”). The Common Warrants may be exercised for either shares of common stock or pre-funded warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the Pre-Funded Warrant (the “Exchange Warrants”). Each Pre-Funded Warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million. The Company raised $4.0 million in gross proceeds and net proceeds were approximately $3.4 million after deducting offering expenses. The warrants have a combined fair value of approximately $5.0 million at issuance and are classified as derivative warrant liabilities. The resulting offset is recorded in other expense along with the issuance costs of $0.6 million in the consolidated financial statement of operations (See Note 16 – Warrants).

Equity Incentive Plans

Equity Incentive Plans	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity Incentive Plans	15. Equity Incentive Plans 2023 Equity Incentive Plan. On May 18, 2023, the Company’s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”). Prior to the Company’s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the “Neos 2015 Plan”, and collectively with the Aytu 2015 Plan, the “2015 Plans”). For the 2023 Equity Incentive Plan, the stockholders approved (a) Stock options granted under the have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years . The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years . Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu 2015 Plan, which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years . The restricted stock awards have a vesting period ranging from 4 to 10 years , whereas the restricted stock units have a vesting period of 4 years . Neos 2015 Plan. Stock Options Stock option activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2023 52,762 ​ $ 18.37 9.06 Granted 112,000 ​ ​ 1.73 Forfeited/Cancelled (2,045) ​ ​ 4.78 Expired (34) ​ ​ 158.09 Outstanding at September 30, 2023 162,683 ​ $ 6.91 9.55 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at September 30, 2023 3,019 ​ $ 227.16 5.97 ​ During the three months ended September 30, 2023, 112,000 stock options were granted. The weighted-average grant date fair value of options granted during the three months ended September 30, 2023 was $1.73. As of September 30, 2023, there was $0.3 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.7 years. Restricted Stock Restricted stock activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2023 38,075 ​ $ 142.20 Granted 12,500 ​ ​ 1.77 Vested (6,424) ​ ​ 137.95 Unvested at September 30, 2023 44,151 ​ $ 103.06 ​ As of September 30, 2023, there was $2.8 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.8 years. As of September 30, 2023, there was total Restricted Stock Units Restricted stock units (RSUs) activity is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2023 4,963 ​ $ 25.62 Vested (561) ​ ​ 24.28 Forfeited ​ (939) ​ ​ 31.60 Unvested at September 30, 2023 3,463 ​ $ 24.21 ​ As of September 30, 2023, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.4 years. Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ September 30, ​ ​ 2023 2022 ​ ​ ​ ​ (in thousands) ​ Cost of sales ​ $ — ​ $ 5 ​ Research and development ​ ​ 1 ​ ​ 9 ​ Selling and marketing ​ ​ — ​ ​ 3 ​ General and Administrative ​ 929 ​ 1,160 ​ Total stock-based compensation expense ​ $ 930 ​ $ 1,177 ​

Warrants

Warrants	3 Months Ended
	Sep. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrants	16. Warrants Liability Classified Warrants On June 8, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company issued and sold an aggregate of (i) 1,743,695 shares of the Company’s common stock, (ii) pre-funded warrants in lieu of shares to purchase 430,217 shares of common stock, (iii) accompanying Tranche A Warrants to purchase 2,173,912 shares of common stock, (iv) and accompanying Tranche B Warrants to purchase 2,173,912 shares of common stock in a best-efforts offering. The Tranche A Warrants and Tranche B Warrants may be exercised for either shares of common stock or pre-funded exchange warrants to purchase common stock at a future exercise price of $0.0001 per share in the same form as the pre-funded warrant. Each pre-funded warrant is exercisable for one share of common stock at an exercise price of $0.0001 per share. The pre-funded warrants are immediately exercisable and may be exercised at any time until all of the pre-funded warrants are exercised in full. The Tranche A Warrants and Tranche B Warrants are immediately exercisable at a price of $1.59 per share (or $1.5899 per pre-funded exchange warrant). The Tranche A Warrants will expire upon the earlier of (i) five years after the date of issuance, and (ii) 30 days following the closing price of the Company’s common stock equaling 200% of the exercise price ($3.18 per share) for at least 40 consecutive trading days. The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Company’s achievement of consolidated trailing twelve-month adjusted EBITDA (as defined in the Securities Purchase Agreement) of $12 million (see Note 14 – Capital Structure). On August 11, 2022, the Company closed an offering (the “August 2022 Offering”), pursuant to which, the Company issued pre-funded warrants to purchase 87,500 shares of its common stock and common warrants to purchase 1,265,547 shares of its common stock. The shares of common stock and the pre-funded warrants were each sold in combination with corresponding common warrants, which one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant was sold. The pre-funded warrants had an exercise price of $0.02 per share of common stock and were exercised in full in August 2022. The common warrants have an exercise price of $8.60 per share of common stock and are exercisable for a period of five years from issuance. The common warrants provide that if there occurs any a stock split, stock dividend stock recapitalization, or similar event (a “Stock Combination Event”), then the warrant exercise price will be adjusted to the greater of the quotient determined by dividing (x) the sum of the VWAP of the common stock for each of the five lowest trading days during the 20 consecutive trading day period ending immediately preceding the 16th trading day after such Stock Combination Event, divided by (y) five; or $2.32, and the number of shares of common stock to be issued would be adjusted proportionately as set forth in the agreement limited to a maximum of 2,325,581 shares. The common warrants also provide that in the event the Company were to engage in an equity offering at a common stock price lower than the warrant exercise price prior to the second anniversary of a Stock Combination Event, the exercise price would be adjusted to the greater of the effective price of such equity offering or $2.32 (see Note 14 – Capital Structure). In November 2022 and throughout the quarter ended December 31, 2022, the Company sold shares through its ATM Sales Agreement. Per the warrant agreement in the August 2022 Offering, these sales qualified as an equity offering and the sales price was less than the current the exercise price of $8.60. As a result, the common warrants exercise price was adjusted to $3.30. On January 6, 2023, the Company consummated a 20 Outstanding warrants are classified as derivative warrant liabilities in the consolidated balance sheets and are marked to market at each reporting period (see Note 12 – Fair Value Considerations). A summary of warrants is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2023 6,538,052 ​ $ 4.42 4.71 Outstanding September 30, 2023 6,538,052 ​ $ 4.42 4.46

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Net Loss Per Common Share	17. Net Loss per Common Share Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted net loss per share reflects the potential of securities that could share in the net loss of the Company. The following table sets forth securities that are considered anti-dilutive, and therefore excluded from the calculation of diluted earnings per share. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2023 2022 Warrants to purchase common stock - liability classified ​ ​ 6,498,980 1,642,235 Warrant to purchase common stock - equity classified ​ ​ 39,072 56,486 Employee stock options ​ ​ 162,683 3,799 Employee unvested restricted stock ​ ​ 46,656 73,164 Employee unvested restricted stock units ​ ​ ​ 3,463 ​ 8,500 Total ​ ​ ​ 6,750,854 1,784,184

License Agreements

License Agreements	3 Months Ended
	Sep. 30, 2023
License Agreement [Abstract]
License Agreements	18. License Agreements Healight In April 2020, the Company entered into a licensing agreement with Cedars-Sinai Medical Center to secure worldwide rights to various potential esophageal and nasopharyngeal uses of Healight, an investigational medical device. The agreement with Cedars-Sinai granted the Company a license to all patent and development related technology rights for the intra-corporeal therapeutic use of ultraviolet light in the field of endotracheal and nasopharyngeal applications. As a result of the focus on revenue growth of the Company’s commercial business, it terminated the licensing agreement with Cedars-Sinai Medical Center, effective May 9, 2023. NeuRx In October 2018, Neos entered into an Exclusive License Agreement (“NeuRx License”) with NeuRx Pharmaceuticals LLC (“NeuRx”), pursuant to which NeuRx granted Neos an exclusive, worldwide, royalty-bearing license to research, develop, manufacture, and commercialize certain pharmaceutical products containing NeuRx’s proprietary compound designated as NRX-101, referred to as NT0502. NT0502 is a new chemical entity that is being developed for the treatment of sialorrhea, which is excessive salivation or drooling. The Company may be required to make certain development and milestone payments and royalties based on annual net sales, as defined in the NeuRx License. Royalties are to be paid on a country-by-country and licensed product-by-licensed product basis, during the period of time beginning on the first commercial sale of such licensed product in such country and continuing until the later of: (i) the expiration of the last-to-expire valid claim in any licensed patent in such country that covers such licensed product in such country; and/or (ii) expiration of regulatory exclusivity of such licensed product in such country. In April 2023, the Company returned the NT0502 rights to NeuRx in exchange for and receive a royalty and potential milestone payments on amounts received for future revenue generated by NeuRx (or a future licensee) on NT0502. Teva On December 21, 2018, Neos and Teva Pharmaceuticals USA, Inc. (“Teva”) entered into an agreement granting Teva a non-exclusive license to certain patents owned by Neos by which Teva has the right to manufacture and market its generic version of Cotempla XR-ODT under an Abbreviated New Drug Application (“ANDA”) filed by Teva beginning on July 1, 2026, or earlier under certain circumstances. Actavis On October 17, 2017, Neos entered into an agreement granting Actavis a non-exclusive license to certain patents owned by Neos by which Actavis (now Teva, following Teva’s acquisition of Actavis’ generic products) has the right to manufacture and market its generic version of Adzenys XR-ODT under its ANDA beginning on September 1, 2025, or earlier under certain circumstances. Shire In July 2014, Neos entered into a Settlement Agreement and an associated License Agreement (the “2014 License Agreement”) with Shire LLC (“Shire”) for a non-exclusive license to certain patents for certain activities with respect to Neos’ New Drug Application (the “NDA”) No. 204326 for an extended-release orally disintegrating amphetamine polistirex tablet. In accordance with the terms of the 2014 License Agreement, following the receipt of the approval from the FDA for Adzenys XR-ODT, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in February 2016. Neos paid a single digit royalty on net sales of Adzenys XR-ODT during the life of the patents. The settlement agreement expired May of 2023, with no further royalties owed from then forward. In March 2017, Neos entered into a License Agreement (the “2017 License Agreement”) with Shire, pursuant to which Shire granted Neos a non-exclusive license to certain patents owned by Shire for certain activities with respect to Neos’ NDA No. 204325 for an extended-release amphetamine oral suspension. In accordance with the terms of the 2017 License Agreement, following the receipt of the approval from the FDA for Adzenys ER, Neos paid an up-front, non-refundable license fee of an amount less than $1.0 million in October 2017. Neos was paying a single digit royalty on net sales of Adzenys ER during the life of the patents. Adzenys ER was discontinued as of September 30, 2021, with no further royalties owed. The royalties are recorded as cost of sales in the same period as the net sales upon which they are calculated. Additionally, each of the 2014 and 2017 License Agreements contains a covenant from Shire not to file a patent infringement suit against Neos alleging that Adzenys XR-ODT or Adzenys ER, respectively, infringes the Shire patents. ​

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation.
Prior Period Reclassification	Prior Period Reclassification
Use of Estimates	Use of Estimates Management uses estimates and assumptions relating to reporting amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for credit losses, determination of variable consideration for accruals of chargebacks, administrative fees and rebates, government rebates, returns and other allowances, write-downs for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, determination of right-of-use assets and lease liabilities, the depreciable lives of long-lived assets, classification of warrants equity versus liability, and the valuation of warrants and derivative warrant liability. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Warrants	Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB Accounting Standards Codification (“ASC”) 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Liability and equity classified warrants are valued using a Black-Scholes option model or Monte Carlo simulation model at issuance and for each reporting period when applicable.
Income Taxes	Income Taxes The Company calculates its quarterly income tax provision based on estimated annual effective tax rates applied to ordinary income (or loss) and other known items computed and recognized when they occur. There have been no changes in tax law affecting the tax provision during the three months ended September 30, 2023. An ownership change (generally a 50% change in equity ownership over a three-year period) could limit the Company’s ability to offset, post-change, U.S. federal taxable income. Section 382 of the Internal Revenue Code imposes an annual limitation on the amount of post-ownership change taxable income a corporation may offset with pre-ownership change net operating loss carryforwards and certain recognized built-in losses. The Company believes that previous acquisitions, financing transactions, and equity ownership changes in the past five years have caused a limitation on its ability to use the pre-acquisition net operating loss carryovers. The ownership change scenario could result in increased future tax liability.
Employee Retention Credit	Employee Retention Credit On March 27, 2020, the U.S. government enacted the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act") to provide certain relief as a result of the COVID-19 pandemic. The CARES Act provides tax relief, along with other stimulus measures, including a provision for an Employee Retention Credit (“ERC”), which allows for employers to claim a refundable payroll tax credit against the employer share of Social Security tax equal to 70% of the qualified wages paid to employees after December 31, 2020 through September 30, 2021. The ERC was designed to encourage businesses to keep employees on the payroll during the COVID-19 pandemic. As there is no authoritative guidance under U.S. GAAP on accounting for government assistance to for-profit business entities, the Company will account for the ERC by analogy to International Accounting Standard ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance. In accordance with IAS 20, when management determines reasonable assurance that the Company had substantially met all eligibility requirements of the ERC, the ERC benefit shall either be recorded as an offset against payroll costs or recognized as other income in the consolidated statement of operations (see Note – 9 Other Liabilities).
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recent Adopted Accounting Pronouncements Financial Instruments Credit Losses. ASU 2016-13, “Financial Instruments – Credit Losses” 15, 2022. The effective dates for the amendments in ASU 2022-02 align with those of ASU 2016-13. The Company had adopted ASU 2016-13 and ASU 2019-05 for the fiscal year ended June 30, 2024. The Company had evaluated the impact of adoption of ASUs 2016-13, 2019-05, and 2022-02 and concluded that the application of the new standards did not have a material impact on the Company’s consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted Debt—Debt with Conversion and Other Options. Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40)— “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” does not expect the adoption of the standard to have a material impact on the Company’s consolidated financial statements. For a complete set of the Company’s significant accounting policies, refer to our Annual Report on Form 10-K for the fiscal year ended June 30, 2023. Other than the application of IAS 20 for the Employee Retention Credit, there have been no significant changes to the Company’s significant accounting policies during the three months ended September 30, 2023.

Revenues from Contracts with _2

Revenues from Contracts with Customers (Tables)	3 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ 2023 2022 ​ ​ (In thousands) Consolidated revenue: ​ ​ ​ Rx Segment ​ $ 17,817 ​ $ 18,652 Consumer Health Segment ​ 4,282 ​ 9,003 Total consolidated revenue ​ $ 22,099 ​ $ 27,655
Schedule of revenue by product lines	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ ​ 2023 2022 ​ ​ (In thousands) Rx Segment: ​ ​ ​ ​ ​ ​ ADHD Portfolio ​ $ 15,128 ​ $ 11,585 Pediatric Portfolio ​ ​ 2,565 ​ ​ 6,558 Other ​ ​ 124 ​ ​ 509 Total Rx Segment revenue ​ $ 17,817 ​ $ 18,652

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory balances	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ (In thousands) Raw materials $ 1,968 $ 1,301 Work in process ​ ​ 3,288 ​ ​ 2,956 Finished goods ​ 7,710 ​ 7,738 Inventories ​ $ 12,966 ​ $ 11,995

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Manufacturing equipment ​ $ 2,433 $ 2,433 Leasehold improvements 999 ​ 999 Office equipment, furniture and other 1,125 ​ 1,125 Lab equipment 832 ​ 832 Assets under construction ​ ​ 323 ​ ​ 107 Property and equipment, gross ​ ​ 5,712 ​ ​ 5,496 Less accumulated depreciation and amortization ​ ​ (3,990) ​ ​ (3,681) Property and equipment, net $ 1,722 ​ $ 1,815

Leases (Tables)

Leases (Tables)	3 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Schedule of components of lease expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ ​ September 30, ​ ​ ​ 2023 2022 Statement of Operations Classification ​ ​ (In thousands) ​ ​ Lease cost: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease cost ​ $ 360 ​ $ 222 Operating expenses Short-term lease cost 23 ​ 160 Operating expenses Finance lease cost: ​ ​ ​ ​ ​ ​ Amortization of leased assets 14 ​ 18 Cost of sales Interest on lease liabilities ​ ​ 1 ​ ​ 3 ​ Other expense, net Total net lease cost $ 398 ​ $ 403
Schedule of balance sheet information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, Balance Sheet Classification ​ ​ 2023 ​ 2023 ​ ​ ​ ​ (In thousands) ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ Operating lease assets * ​ $ 2,454 ​ $ 2,054 Operating lease right-of-use asset Finance lease assets ​ ​ — ​ 159 Property and equipment, net Total leased assets ​ $ 2,454 ​ $ 2,213 ​ Liabilities: ​ ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ $ 1,265 ​ $ 1,258 ​ Other current liabilities Finance leases ​ ​ 62 ​ ​ 85 ​ Current portion of debt Non-current ​ ​ ​ ​ ​ ​ ​ ​ Operating leases ​ ​ 1,208 ​ ​ 832 ​ Other non-current liabilities Total lease liabilities ​ $ 2,535 ​ $ 2,175 ​ ​ ​ * Includes $0.2 million from the Consumer Health Segment as of September 30, 2023 and June 30, 2023.
Schedule of remaining lease term and discount rate	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ Weighted-Average Remaining Lease Term (years) ​ ​ ​ ​ ​ ​ ​ Operating lease assets ​ 2.65 ​ ​ 1.72 ​ Finance lease assets ​ 0.62 ​ ​ 0.87 ​ Weighted-Average Discount Rate ​ ​ ​ ​ ​ ​ Operating lease assets ​ 8.60 % ​ 7.78 % Finance lease assets ​ ​ 6.54 % ​ 6.54 %
Schedule of supplemental cash flow information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ September 30, ​ 2023 2022 ​ ​ (In thousands) Cash flow classification of lease payments: ​ ​ ​ ​ ​ ​ Operating cash flows from operating leases ​ $ 360 ​ $ 357 Operating cash flows from finance leases ​ $ 1 ​ $ 3 Financing cash flows from finance leases ​ $ 23 ​ $ 27
Schedule of maturities of future minimum lease payments, operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 (remaining 9 months) ​ $ 1,035 ​ $ 64 2025 ​ ​ 937 ​ ​ — 2026 ​ ​ 282 ​ ​ — 2027 ​ ​ 241 ​ ​ — 2028 ​ ​ 199 ​ ​ — Thereafter ​ ​ 168 ​ ​ — Total lease payments ​ ​ 2,862 ​ ​ 64 Less: Imputed interest ​ ​ (389) ​ ​ (2) Lease liabilities ​ $ 2,473 ​ $ 62
Schedule of maturities of future minimum lease payments, finance leases	​ ​ ​ ​ ​ ​ ​ ​ ​ Operating Finance ​ ​ (In thousands) 2024 (remaining 9 months) ​ $ 1,035 ​ $ 64 2025 ​ ​ 937 ​ ​ — 2026 ​ ​ 282 ​ ​ — 2027 ​ ​ 241 ​ ​ — 2028 ​ ​ 199 ​ ​ — Thereafter ​ ​ 168 ​ ​ — Total lease payments ​ ​ 2,862 ​ ​ 64 Less: Imputed interest ​ ​ (389) ​ ​ (2) Lease liabilities ​ $ 2,473 ​ $ 62

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (11,683) ​ $ — ​ $ 30,493 11.29 Acquired technology right ​ ​ 30,200 ​ ​ (4,498) ​ ​ — ​ ​ 25,702 ​ 14.50 Acquired product distribution rights ​ 6,207 ​ (5,061) ​ — ​ 1,146 0.75 Total ​ $ 78,583 ​ $ (21,242) ​ $ — ​ $ 57,341 12.52 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67
Schedule of Indefinite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (11,683) ​ $ — ​ $ 30,493 11.29 Acquired technology right ​ ​ 30,200 ​ ​ (4,498) ​ ​ — ​ ​ 25,702 ​ 14.50 Acquired product distribution rights ​ 6,207 ​ (5,061) ​ — ​ 1,146 0.75 Total ​ $ 78,583 ​ $ (21,242) ​ $ — ​ $ 57,341 12.52 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2023 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net ​ Average ​ ​ Carrying ​ Accumulated ​ ​ ​ ​ Carrying ​ Remaining ​ Amount Amortization Impairment Amount Life (in years) ​ ​ (In thousands) Definite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired product technology rights ​ $ 42,176 ​ $ (10,881) ​ $ — ​ $ 31,295 11.49 Acquired technology right ​ ​ 30,200 ​ ​ (4,054) ​ ​ — ​ ​ 26,146 ​ 14.75 Acquired product distribution rights ​ 9,182 ​ (4,678) ​ (2,975) ​ 1,529 1.00 ​ ​ ​ 81,558 ​ ​ (19,613) ​ ​ (2,975) ​ ​ 58,970 ​ 12.67 Indefinite-lived intangibles: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Acquired in-process R&D ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ Indefinite-lived ​ ​ ​ 2,600 ​ ​ — ​ ​ (2,600) ​ ​ — ​ ​ Total ​ $ 84,158 ​ $ (19,613) ​ $ (5,575) ​ $ 58,970 12.67
Schedule of future amortization expense	​ ​ ​ ​ ​ ​ September 30, ​ ​ (In thousands) 2024 (remaining 9 months) ​ $ 4,889 2025 ​ ​ 4,989 2026 ​ ​ 4,989 2027 ​ ​ 4,989 2028 ​ ​ 4,988 Thereafter ​ ​ 32,497 Total future amortization expense ​ $ 57,341

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Sep. 30, 2023
Accrued Liabilities, Current [Abstract]
Schedule of accrued liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Accrued savings offers ​ $ 13,023 ​ $ 15,739 Accrued program liabilities ​ ​ 9,994 ​ ​ 11,012 Accrued employee compensation ​ ​ 5,374 ​ ​ 5,675 Accrued customer and product related fees ​ ​ 4,691 ​ ​ 6,579 Return reserve ​ 5,137 ​ 5,777 Other accrued liabilities ​ ​ 2,511 ​ ​ 2,017 Total accrued liabilities ​ $ 40,730 ​ $ 46,799

Other Liabilities (Tables)

Other Liabilities (Tables)	3 Months Ended
	Sep. 30, 2023
Other Liabilities Disclosure [Abstract]
Schedule of other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ June 30, ​ ​ 2023 ​ 2023 ​ ​ (In thousands) Fixed payment arrangements ​ $ 9,380 ​ $ 10,420 Operating lease liabilities ​ 2,473 ​ 2,090 Employee retention credit ​ ​ 3,759 ​ ​ — Other ​ ​ 1,484 ​ ​ 1,555 Total other liabilities ​ ​ 17,096 ​ ​ 14,065 Less: current portion ​ ​ (8,990) ​ ​ (7,090) Total other liabilities, non-current ​ $ 8,106 ​ $ 6,975

Long-term Debt (Tables)

Long-term Debt (Tables)	3 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of long term debt	​ ​ ​ ​ ​ ​ September 30, ​ ​ 2023 ​ ​ (In thousands) Long-term debt, due on January 26, 2025 ​ $ 15,000 Long-term, final payment fee ​ ​ 638 Unamortized discount and issuance costs ​ ​ (796) Financing leases, maturing through May 2024 ​ ​ 62 Total debt ​ ​ 14,904 Less: current portion ​ ​ (62) Non-current portion of debt ​ $ 14,842
Schedule of future principal payments of long term debt	​ ​ ​ ​ ​ ​ September 30, ​ ​ (In thousands) 2024 ​ $ 62 2025 ​ ​ 15,638 Future principal payments ​ ​ 15,700 Less unamortized discount and issuance costs ​ ​ (796) Less current portion ​ ​ (62) Non-current portion of debt ​ $ 14,842

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at September 30, 2023 ​ Fair Value at September 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ ​ 12,310 ​ — ​ — ​ 12,310 Total ​ $ 12,310 $ — $ — ​ $ 12,310 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value Measurements at June 30, 2023 ​ Fair Value at June 30, ​ ​ ​ ​ ​ 2023 (Level 1) (Level 2) (Level 3) ​ (In thousands) Liabilities: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Derivative warrant liabilities ​ ​ 6,403 ​ ​ — ​ ​ — ​ ​ 6,403 Total ​ $ 6,403 $ — $ — ​ $ 6,403 ​
Schedule of changes in Level 3 inputs	​ ​ ​ ​ ​ ​ Derivative ​ ​ Warrant Liabilities ​ ​ (In thousands) Balance as of June 30, 2023 $ 6,403 Included in earnings ​ 5,907 Balance as of September 30, 2023 $ 12,310 ​
Schedule of significant assumptions used in valuation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 2023 Warrants ​ Warrants ​ Tranche A & B Other * Valuation methodology ​ Monte Carlo Simulation ​ ​ ​ ​ ​ ​ & Black-Scholes ​ ​ Black-Scholes ​ Equivalent term (years) ​ 4.69 ​ ​ 3.34-3.94 ​ Expected volatility 93.32 % 93.32 % Risk-free rate ​ 4.63 % ​ 4.70-4.78 % Dividend yield ​ 0.00 % ​ 0.00 % ​ ​ ​ ​ ​ ​ ​ * Includes August 2022 Warrants, March 2022 Warrants, and Avenue Capital Warrants.

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	3 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Options ​ Exercise Price ​ Life in Years Outstanding June 30, 2023 52,762 ​ $ 18.37 9.06 Granted 112,000 ​ ​ 1.73 Forfeited/Cancelled (2,045) ​ ​ 4.78 Expired (34) ​ ​ 158.09 Outstanding at September 30, 2023 162,683 ​ $ 6.91 9.55 ​ ​ ​ ​ ​ ​ ​ ​ Exercisable at September 30, 2023 3,019 ​ $ 227.16 5.97 ​
Restricted stock activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2023 38,075 ​ $ 142.20 Granted 12,500 ​ ​ 1.77 Vested (6,424) ​ ​ 137.95 Unvested at September 30, 2023 44,151 ​ $ 103.06 ​
Restricted stock units activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ Average Grant ​ ​ Number of ​ Date Fair ​ ​ Shares ​ Value Unvested at June 30, 2023 4,963 ​ $ 25.62 Vested (561) ​ ​ 24.28 Forfeited ​ (939) ​ ​ 31.60 Unvested at September 30, 2023 3,463 ​ $ 24.21
Stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ ​ ​ September 30, ​ ​ 2023 2022 ​ ​ ​ ​ (in thousands) ​ Cost of sales ​ $ — ​ $ 5 ​ Research and development ​ ​ 1 ​ ​ 9 ​ Selling and marketing ​ ​ — ​ ​ 3 ​ General and Administrative ​ 929 ​ 1,160 ​ Total stock-based compensation expense ​ $ 930 ​ $ 1,177 ​

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Sep. 30, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of warrants	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Average ​ ​ ​ ​ Weighted ​ Remaining ​ ​ Number of ​ Average ​ Contractual ​ ​ Warrants ​ Exercise Price ​ Life in Years Outstanding June 30, 2023 6,538,052 ​ $ 4.42 4.71 Outstanding September 30, 2023 6,538,052 ​ $ 4.42 4.46

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Antidilutive securities excluded from the computation of earnings per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2023 2022 Warrants to purchase common stock - liability classified ​ ​ 6,498,980 1,642,235 Warrant to purchase common stock - equity classified ​ ​ 39,072 56,486 Employee stock options ​ ​ 162,683 3,799 Employee unvested restricted stock ​ ​ 46,656 73,164 Employee unvested restricted stock units ​ ​ ​ 3,463 ​ 8,500 Total ​ ​ ​ 6,750,854 1,784,184

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of segment select financial information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Rx ​ ​ Consumer Health ​ ​ Consolidated ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 17,817 ​ $ 4,282 ​ $ 22,099 Loss from operations $ (866) ​ $ (638) ​ $ (1,504) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 1,554 ​ $ 387 ​ $ 1,941 Stock based compensation $ 725 ​ $ 205 ​ $ 930 ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue, net $ 18,652 ​ $ 9,003 ​ $ 27,655 Loss from operations $ (993) ​ $ (815) ​ $ (1,808) ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation and amortization $ 1,574 ​ $ 281 ​ $ 1,855 Stock based compensation $ 1,162 ​ $ 15 ​ $ 1,177

Nature of Business, Financial_2

Nature of Business, Financial Condition, Basis of Presentation - Segments (Details) - segment	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Nature of Business, Financial_3

Nature of Business, Financial Condition, Basis of Presentation - Reverse Stock Split (Details)	Jan. 06, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stock split, conversion ratio	0.05

Nature of Business, Financial_4

Nature of Business, Financial Condition, Basis of Presentation - Product Information (Details) - item	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Rx
Disaggregation of Revenue [Line Items]
Number of product portfolios	2	2

Nature of Business, Financial_5

Nature of Business, Financial Condition, Basis of Presentation - General Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash, cash equivalents and restricted cash	$ 19,964	$ 23,811	$ 22,985	$ 19,360
Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]
Accounts receivable, net	29,882		28,937
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	(8,120)	(701)
Retained Earnings (Accumulated Deficit) [Abstract]
Accumulated deficit	(312,249)		$ (304,129)
Net Cash Provided by (Used in) Operating Activities [Abstract]
Cash used in operations	$ (211)	$ (9,148)

Nature of Business, Financial_6

Nature of Business, Financial Condition, Basis of Presentation - Debt (Details) - USD ($) $ in Millions	Sep. 30, 2023	Jan. 26, 2022
Avenue Capital Loan, Term Loan
Debt Instrument [Line Items]
Face amount	$ 15	$ 15

Nature of Business, Financial_7

Nature of Business, Financial Condition, Basis of Presentation - Going Concern (Details)	3 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern, within One Year	true

Significant Accounting Polici_3

Significant Accounting Policies - Recent Accounting Pronouncements (Details)	Sep. 30, 2023
Accounting Standards Update 2020-06
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	false

Revenues from Contracts with _3

Revenues from Contracts with Customers - Revenues by Segment (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 22,099	$ 27,655
Rx
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	17,817	18,652
Consumer Health Segment
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 4,282	$ 9,003

Revenues from Contracts with _4

Revenues from Contracts with Customers - Revenues by Product Portfolio (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 22,099	$ 27,655
ADHD
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 15,128	11,585
Reporting Unit, Name of Segment	Rx
Pediatric
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 2,565	6,558
Reporting Unit, Name of Segment	Rx
Other
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 124	509
Reporting Unit, Name of Segment	Rx
Rx
Disaggregation of Revenue [Line Items]
Revenue from contract with customer	$ 17,817	$ 18,652

Inventories - Inventory Write-d

Inventories - Inventory Write-down (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Production Related Impairments or Charges [Abstract]
Inventory write-down	$ 51	$ 82

Inventories - Tabular Disclosur

Inventories - Tabular Disclosure (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Inventory, Net [Abstract]
Raw materials	$ 1,968	$ 1,301
Work in process	3,288	2,956
Finished goods	7,710	7,738
Inventories	$ 12,966	$ 11,995

Property and Equipment - Tabula

Property and Equipment - Tabular Disclosure (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 5,712	$ 5,496
Less accumulated depreciation and amortization	(3,990)	(3,681)
Property and equipment, net	1,722	1,815
Manufacturing Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	2,433	2,433
Leasehold Improvements
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	999	999
Office Equipment, Furniture and Other
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	1,125	1,125
Lab Equipment
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	832	832
Asset under Construction
Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization [Abstract]
Property and equipment, gross	$ 323	$ 107

Property and Equipment - Deprec

Property and Equipment - Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Depreciation, Depletion and Amortization [Abstract]
Depreciation expense	$ 0.3	$ 0.3

Leases - General Information (D

Leases - General Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset	$ 2,454	$ 2,054
Operating lease liabilities	$ 2,473	$ 2,090
Most Leases
Lessee, Operating Lease, Description [Abstract]
Lessee, Operating Lease, Existence of Option to Extend	true
Principal Office, Denver, Colorado
Lessee, Operating Lease, Description [Abstract]
Operating lease right-of-use asset	$ 700
Operating lease liabilities	$ 700
Operating lease, borrowing rate (as a percent)	10.30%
Lessee, operating lease, term of contract	5 years 6 months
Lease, Practical Expedient, Lessor Single Lease Component	true

Leases - Net Lease Cost (Detail

Leases - Net Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Lease, Cost [Abstract]
Operating lease cost	$ 360	$ 222
Short-term lease cost	23	160
Amortization of leased assets	14	18
Interest on lease liabilities	1	3
Total net lease cost	$ 398	$ 403

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information - Tabular Disclosure (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 2,454	$ 2,054
Finance lease assets		$ 159
Finance Lease, Right-of-Use Asset, Statement of Financial Position	Property and equipment, net	Property and equipment, net
Total leased assets	$ 2,454	$ 2,213
Current portion of operating lease liabilities	$ 1,265	$ 1,258
Operating Lease, Liability, Current, Statement of Financial Position	Other current liabilities	Other current liabilities
Finance leases, current	$ 62	$ 85
Finance Lease, Liability, Current, Statement of Financial Position	Current portion of debt	Current portion of debt
Operating lease liabilities, net of current portion	$ 1,208	$ 832
Total lease liabilities	$ 2,535	$ 2,175

Leases - Supplemental Balance_2

Leases - Supplemental Balance Sheet Information - Segment Information (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 2,454	$ 2,054
Consumer Health Segment
Assets and Liabilities, Lessee [Abstract]
Operating lease assets	$ 200	$ 200

Leases - Remaining Lease Term a

Leases - Remaining Lease Term and Weighted-average Discount Rate (Details)	Sep. 30, 2023	Jun. 30, 2023
Lessee Disclosure [Abstract]
Operating lease assets, weighted-average remaining lease term	2 years 7 months 24 days	1 year 8 months 19 days
Finance lease assets, weighted-average remaining lease term	7 months 13 days	10 months 13 days
Operating lease assets, weighted-average discount rate	8.60%	7.78%
Finance lease assets, weighted-average discount rate	6.54%	6.54%

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flow, Operating Activities, Lessee [Abstract]
Operating cash flows from operating leases	$ 360	$ 357
Cash Flow, Investing Activities, Lessee [Abstract]
Operating cash flows from finance leases	1	3
Cash Flow, Financing Activities, Lessee [Abstract]
Financing cash flows from finance leases	$ 23	$ 27

Leases - Operating Leases - Fut

Leases - Operating Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2024 (remaining 9 months)	$ 1,035
2025	937
2026	282
2027	241
2028	199
Thereafter	168
Total lease payments	$ 2,862

Leases - Operating Leases - Gro

Leases - Operating Leases - Gross Difference (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Operating Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 2,862
Less: Imputed interest	(389)
Lease liabilities	$ 2,473	$ 2,090

Leases - Finance Leases - Futur

Leases - Finance Leases - Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Finance Lease, Liability, Payment, Due [Abstract]
2024 (remaining 9 months)	$ 64
Total lease payments	$ 64

Leases - Finance Leases - Gross

Leases - Finance Leases - Gross Difference (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Finance Lease Liabilities, Gross Difference, Amount [Abstract]
Total lease payments	$ 64
Less: Imputed interest	(2)
Lease liabilities	$ 62

Intangible Assets - Finite-live

Intangible Assets - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 78,583	$ 81,558
Finite-lived intangible assets, accumulated amortization	(21,242)	(19,613)
Finite-lived intangible assets, accumulated impairment		(2,975)
Finite-lived intangible assets, net carrying amount	57,341	58,970
Acquired product technology right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	42,176	42,176
Finite-lived intangible assets, accumulated amortization	(11,683)	(10,881)
Finite-lived intangible assets, net carrying amount	30,493	31,295
Acquired technology right
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	30,200	30,200
Finite-lived intangible assets, accumulated amortization	(4,498)	(4,054)
Finite-lived intangible assets, net carrying amount	25,702	26,146
Acquired product distribution rights
Finite-Lived Intangible Assets, Net [Abstract]
Finite-lived intangible assets, gross carrying amount	6,207	9,182
Finite-lived intangible assets, accumulated amortization	(5,061)	(4,678)
Finite-lived intangible assets, accumulated impairment		(2,975)
Finite-lived intangible assets, net carrying amount	$ 1,146	$ 1,529

Intangible Assets - Weighted-av

Intangible Assets - Weighted-average Remaining Life (Details) - Weighted Average	Sep. 30, 2023	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	12 years 6 months 7 days	12 years 8 months 1 day
Acquired product technology right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	11 years 3 months 14 days	11 years 5 months 26 days
Acquired technology right
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	14 years 6 months	14 years 9 months
Acquired product distribution rights
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, remaining amortization period	9 months	1 year

Intangible Assets - Indefinite-

Intangible Assets - Indefinite-lived Intangible Assets (Details) $ in Thousands	Jun. 30, 2023 USD ($)
Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]
Indefinite-lived intangible assets, before accumulated impairment	$ 2,600
Indefinite-lived intangible assets, accumulated impairment	$ (2,600)

Intangible Assets - Intangible

Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Finite-lived intangible assets, gross carrying amount	$ 78,583	$ 81,558
Indefinite-lived intangible assets, before accumulated impairment		2,600
Intangible assets, gross carrying amount	78,583	84,158
Finite-lived intangible assets, accumulated amortization	(21,242)	(19,613)
Finite-lived intangible assets, accumulated impairment		(2,975)
Indefinite-lived intangible assets, accumulated impairment		(2,600)
Impairment		(5,575)
Intangible assets, net carrying amount	$ 57,341	$ 58,970

Intangible Assets - Estimated F

Intangible Assets - Estimated Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2024 (remaining 9 months)	$ 4,889
2025	4,989
2026	4,989
2027	4,989
2028	4,988
Thereafter	32,497
Finite-lived intangible assets, net carrying amount	$ 57,341	$ 58,970

Intangible Assets - Supply and

Intangible Assets - Supply and Distribution Agreement (Details)	3 Months Ended
	Sep. 30, 2023
Supply and Distribution Agreement, Tris Pharma, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years

Intangible Assets - Estimated U

Intangible Assets - Estimated Useful Life (Details)	3 Months Ended
	Sep. 30, 2023
Minimum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	1 year
Maximum
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible asset, useful life, renewable period	20 years
Product Technology Right | Attention Deficit Hyperactivity Disorder Portfolio
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	17 years

Intangible Assets - Product Dis

Intangible Assets - Product Distribution Rights and Customer List (Details) - Innovus Pharmaceuticals, Inc $ in Millions	1 Months Ended	12 Months Ended
	Feb. 29, 2020 item product	Jun. 30, 2023 USD ($)
Business Acquisition [Line Items]
Number of products acquired | product	35
Number of registered trademarks and or patent rights and customer lists acquired | item	300
Consumer Health Segment
Business Acquisition [Line Items]
Impairment of intangible assets, finite-lived | $		$ 3

Intangible Assets - Amortizatio

Intangible Assets - Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Amortization [Abstract]
Amortization expense	$ 1.6	$ 1.5

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Accrued Liabilities, Current [Abstract]
Accrued savings offers	$ 13,023	$ 15,739
Accrued program liabilities	9,994	11,012
Accrued employee compensation	5,374	5,675
Accrued customer and product related fees	4,691	6,579
Return reserve	5,137	5,777
Other accrued liabilities	2,511	2,017
Total accrued liabilities	$ 40,730	$ 46,799

Other Liabilities - Components

Other Liabilities - Components (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Other Liabilities, Unclassified [Abstract]
Fixed payment arrangements	$ 9,380	$ 10,420
Operating lease liabilities	2,473	2,090
Employee retention credit	3,759
Other	1,484	1,555
Total other liabilities	$ 17,096	$ 14,065

Other Liabilities - Classificat

Other Liabilities - Classification (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Other Liabilities [Abstract]
Total other liabilities	$ 17,096	$ 14,065
Less: current portion	(8,990)	(7,090)
Total other liabilities, non-current	$ 8,106	$ 6,975

Other Liabilities - Fixed Payme

Other Liabilities - Fixed Payment Arrangements (Details) $ in Thousands				1 Months Ended
	May 12, 2022 USD ($)	Jun. 21, 2021 USD ($)	May 29, 2020 USD ($)	Jan. 31, 2021 USD ($)	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($)	Sep. 30, 2021 USD ($) payment	Nov. 01, 2019 USD ($)
Other Commitments [Line Items]
Fixed payment arrangements					$ 9,380	$ 10,420
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Fixed Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly payment amount								$ 100
Fixed payment arrangements, balloon payment amount								$ 15,000
Fixed payment arrangements, balloon payment amount, paid			$ 15,000
Fixed payment arrangements							$ 3,000
Fixed payment arrangements, quarterly payment amount, payments, number | payment							6
Fixed payment arrangements, quarterly payment amount							$ 500
Fixed Payment Arrangements, Investor Assumed, Product Acquisition from Cerecor, Inc, Periodic Payment Obligation, Variable Payments
Other Commitments [Line Items]
Fixed payment arrangements, monthly variable payment amount, percentage of net revenue (as a percent)								15%
Fixed payment arrangements, monthly variable payment amount, minimum								$ 100
Fixed payment arrangements, monthly variable payment amount, one-time payment, paid				$ 200
Fixed payment arrangements, monthly variable payment amount, aggregate payments to satisfy obligation if paid before 12 February 2026								$ 9,300
Fixed payment arrangements, payment amount, paid		$ 2,800
Fixed Payment Arrangements, Termination of Original License Agreement, Tris Pharma, Inc
Other Commitments [Line Items]
Fixed payment arrangements	$ 9,000
Fixed payment arrangements, current					6,000
Fixed payment arrangements, liability, reduction	$ 8,000
Fixed Payment Arrangements, TRIS Pharma, Inc, Royalty and Make Whole Payments
Other Commitments [Line Items]
Fixed payment arrangements, current					1,800
Fixed payment arrangements, noncurrent					$ 1,700

Other Liabilities - Supply and

Other Liabilities - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	3 Months Ended
	Sep. 30, 2023 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Other Liabilities - Contingent

Other Liabilities - Contingent Consideration - Employee Retention Credit (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Other Liabilities Disclosure [Abstract]
Proceeds from ERC program	$ 3.8
Employee retention credit, vendor fee	$ 0.4

Line of Credit (Details)

Line of Credit (Details) $ in Thousands			1 Months Ended	3 Months Ended
	Mar. 24, 2023 USD ($)	Jan. 26, 2022 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2023 USD ($) D	Sep. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)
Short-Term Debt [Line Items]
Short-term line of credit				$ 1,215		$ 1,563
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity, increase (decrease)	$ 2,000
Maximum borrowing capacity	$ 14,500	$ 12,500	$ 25,000
Unused capacity commitment fee (as a percent)			0.50%
Debt instrument, maturity date		Jan. 26, 2025	May 11, 2022
Availability block		$ 3,500	$ 1,000
Termination fee before 26 January 2023 (as a percent)				2%
Termination fee after 26 January 2023, but before 26 January 2024 (as a percent)				1%
Termination fee after 26 January 2024, but on or before 26 January 2025 (as a percent)				0.50%
Notice period | D				5
Interest expense including amortization of deferred financing costs				$ 27	$ 100
Short-term line of credit				$ 1,200		$ 1,600
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate
Short-Term Debt [Line Items]
Basis spread on variable rate (as a percent)			4.50%
Secured Debt | Eclipse Loan Agreement, Secured Revolving Loans, Short-term Swingline Loans
Short-Term Debt [Line Items]
Maximum borrowing capacity			$ 2,500
Maximum borrowing capacity, percentage of eligible accounts receivable (as a percent)			85%

Long-term Debt - Narrative (Det

Long-term Debt - Narrative (Details) - Avenue Capital Loan, Term Loan - USD ($) $ in Millions		3 Months Ended
	Jan. 26, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Debt instrument, minimum variable rate before basis spread (as a percent)	3.25%
Debt instrument, basis spread on variable rate (as a percent)	7.40%
Face amount	$ 15	$ 15
Debt instrument, interest payment term	18 months
Debt instrument, interest payment extension term	6 months
Interest-only period, further extension term	12 months
Debt instrument, term of trailing months revenue	12 months
Debt instrument, prepayment fee percentage (as a percent)	3%
Loan origination, legal and other fees	$ 0.4
Debt instrument, interest rate, effective percentage (as a percent)		19.60%
Interest expense including amortization of deferred financing costs		$ 0.7	$ 0.6
Event occurs after January 26, 2023, but on or before January 26, 2024
Debt Instrument [Line Items]
Debt instrument, prepayment fee percentage (as a percent)	2%
Event occurs after January 26, 2024, but on or before January 26, 2025
Debt Instrument [Line Items]
Debt instrument, prepayment fee percentage (as a percent)	1%

Long-term Debt - Warrants (Deta

Long-term Debt - Warrants (Details) - USD ($) $ / shares in Units, $ in Millions	Mar. 07, 2022	Jan. 26, 2022	Oct. 25, 2022
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 25
Warrants to Purchase Common Stock, Equity Classified, Avenue Capital Warrants, January 2022 [Member]
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Mar. 07, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 24.20		$ 8.60
Class of warrant or right, number of securities called by warrants or right (in shares)	43,388
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 24.20
Fair value of warrants		$ 0.6

Long-term Debt - Composition (D

Long-term Debt - Composition (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Debt Disclosure [Abstract]
Long-term debt, due on January 26, 2025	$ 15,000
Long-term, final payment fee	638
Unamortized discount	(796)
Financing leases, maturing through May 2024	62
Total debt	14,904
Less current portion	(62)	$ (85)
Non-current portion of debt	$ 14,842	$ 14,713

Long-term Debt - Future Princip

Long-term Debt - Future Principal Payments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Debt Disclosure [Abstract]
2024	$ 62
2025	15,638
Future principal payments	15,700
Less unamortized discount and issuance costs	(796)
Less current portion	(62)	$ (85)
Non-current portion of debt	$ 14,842	$ 14,713

Fair Value Considerations - Rec

Fair Value Considerations - Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023
Financial Liabilities Fair Value Disclosure [Abstract]
Derivative Liability, Statement of Financial Position	Derivative warrant liabilities	Derivative warrant liabilities
Fair Value, Recurring
Financial Liabilities Fair Value Disclosure [Abstract]
Derivative warrant liabilities	$ 12,310	$ 6,403
Total	12,310	6,403
Fair Value, Recurring | Fair Value, Inputs, Level 3
Financial Liabilities Fair Value Disclosure [Abstract]
Derivative warrant liabilities	12,310	6,403
Total	$ 12,310	$ 6,403

Fair Value Considerations - Uno

Fair Value Considerations - Unobservable Inputs Reconciliation, Recurring Basis, Liabilities (Details) - Derivative Financial Instruments, Liabilities $ in Thousands	3 Months Ended
	Sep. 30, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 6,403
Included in earnings	5,907
Ending balance	$ 12,310

Fair Value Measurements - Valua

Fair Value Measurements - Valuation Assumptions (Details)	Sep. 30, 2023 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of Monte Carlo simulations	100,000
Measurement Input, Price Volatility | June 2023 Warrants Tranche A And B
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	93.32
Measurement Input, Price Volatility | Other Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	93.32
Measurement Input, Expected Term | June 2023 Warrants Tranche A And B
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.69
Measurement Input, Expected Term | Other Warrants | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.34
Measurement Input, Expected Term | Other Warrants | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	3.94
Measurement Input, Risk Free Interest Rate | June 2023 Warrants Tranche A And B
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.63
Measurement Input, Risk Free Interest Rate | Other Warrants | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.70
Measurement Input, Risk Free Interest Rate | Other Warrants | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	4.78
Measurement Input, Expected Dividend Rate | June 2023 Warrants Tranche A And B
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0
Measurement Input, Expected Dividend Rate | Other Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability, measurement input	0

Commitments and Contingencies -

Commitments and Contingencies - Supply and Distribution Agreement (Details) - Supply and Distribution Agreement, Tris Pharma, Inc	3 Months Ended
	Sep. 30, 2023 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Supply and distribution agreement, term	20 years
Supply and distribution agreement, royalty, percentage of net sales (as a percent)	23.50%
Supply and distribution agreement, minimum unit sales commitments, annual unit sales, units | item	70,000
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, per unit	$ 30
Supply and distribution agreement, minimum unit sales commitments, royalty make whole payment under annual minimum sales commitment, maximum annual amount	2,100,000
Supply and distribution agreement, commercial milestone obligations, cumulative net sales, maximum obligation	3,000,000
Supply and distribution agreement, commercial milestone obligations, net revenue trigger amount	$ 40,000,000

Commitments and Contingencies_2

Commitments and Contingencies - Earn Out Payments (Details) $ in Thousands	Apr. 12, 2021 USD ($)
Commercial Global License Agreements, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, milestone, maximum earn-out, cash and common stock	$ 67,500
Commercial Global License Agreement, Denovo Biopharma LLC, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, license option fee	600
License agreement, escalating royalties, maximum	101,700
Commercial Global License Agreement, Johns Hopkins University, AR101
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, minimum annual royalties, low end of range	$ 20
License agreement, royalties, percentage of net product sales (as a percent)	3%
License agreement, royalties, achievement of certain regulatory and commercial milestones, maximum	$ 1,600

Commitments and Contingencies_3

Commitments and Contingencies - Product Contingent Liability (Details) - Product Contingent Liability, Novalere, FlutiCare $ in Millions	Jun. 30, 2023 USD ($)	Feb. 28, 2015 USD ($) payment
Other Commitments [Line Items]
Product contingent liability, additional payments, number, certain sales achieved | payment		5
Product contingent liability, additional payments, amount, certain sales achieved		$ 0.5
Product contingent liability, milestone, payment	$ 0	$ 0

Commitments and Contingencies_4

Commitments and Contingencies - Legal Matters (Details) - Sabby Litigation	Feb. 22, 2023 shares
Sabby Volatility Warrant Master Fund Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Litigation case, class of warrant or right, number of securities called by warrants or rights	575,000
Number of warrants issued to purchase shares (in shares)	312,908
Walleye Opportunities Master Fund Ltd
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Litigation case, class of warrant or right, number of securities called by warrants or rights	100,000
Number of warrants issued to purchase shares (in shares)	54,146

Capital Structure - Common and

Capital Structure - Common and Preferred Stock (Details) - $ / shares	Sep. 30, 2023	Jun. 30, 2023
Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	5,530,235	5,517,174
Common stock, shares outstanding (in shares)	5,530,235	5,517,174
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Capital Structure - Restricted

Capital Structure - Restricted Stock (Details) - shares	Sep. 30, 2023	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	5,530,235	5,517,174
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares outstanding (in shares)	46,656

Capital Structure - Stock Offer

Capital Structure - Stock Offerings (Details) - USD ($) $ in Millions		12 Months Ended
	Aug. 11, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 28, 2021	Jun. 04, 2021	Jun. 08, 2020
Shelf Registration Statement, 2020 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized						$ 100
Shelf Registration Statement, 2020 Shelf, At-the-market Sales Agreement
Subsidiary, Sale of Stock [Line Items]
At-the-market sales agreement, amount authorized					$ 30
Issuance of common stock (in shares)		699,929
Proceeds from issuance of stock, net		$ 2.9
Shelf Registration Statement, 2021 Shelf
Subsidiary, Sale of Stock [Line Items]
Shelf registration, amount authorized				$ 100
Shelf registration, remaining amount available for sale			$ 82.4
Shelf Registration Statement, 2021 Shelf, Underwritten Public Offering, August 2022
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock (in shares)	1,075,290
Proceeds from issuance of common stock and warrants	$ 10
Underwriting discounts, commissions, and other offering expenses	$ 0.9

Capital Structure - Warrants (D

Capital Structure - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended
	Jun. 08, 2023	Aug. 11, 2022	Jan. 26, 2022	Sep. 30, 2022	Aug. 31, 2022
Class of Warrant or Right [Line Items]
Proceeds from issuance of common stock and warrants, net of issuance costs				$ 10,416
Securities Purchase Agreement, 2023, Private Offering, June 2023
Class of Warrant or Right [Line Items]
Proceeds from issuance of common stock and warrants	$ 4,000
Proceeds from issuance of common stock and warrants, net of issuance costs	$ 3,400
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable			Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)			$ 24.20
Fair value of warrants			$ 600
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable		Aug. 11, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 2.32
Class of warrant or right, offering price (in dollars per share)		$ 8.58
Fair value of warrants		$ 6,000
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)		$ 0.02			$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)		1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)		1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 3.30	$ 8.60
Warrants and rights outstanding, term		5 years
Warrants to Purchase Common Stock, Liability Classified, June 2023
Class of Warrant or Right [Line Items]
Issuance of common stock, net of issuance costs (in shares)	1,743,695
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	$ 1.59
Fair value of warrants	$ 5,000
Commission and other costs	$ 600
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	430,217
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	$ 1.5899
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 0.0001
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	$ 1.59
Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Class of warrant or right, exercise price of warrants or rights (in dollars per share)	$ 3.18
Class of warrant or right, exercisable, exercise price of warrants or rights (in dollars per share)	$ 3.18
Warrants and rights outstanding, term	5 years
Class of warrant, term of expiration after closing price of common stock	30 days
Class of warrant or right, percentage of exercise price equaling common stock	200%
Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA	30 days
Adjusted earnings before interest, taxes, depreciation, and amortization	$ 12,000

Equity Incentive Plans - Genera

Equity Incentive Plans - General Information (Details) - shares	May 18, 2023	Mar. 01, 2021	Jun. 01, 2015	Sep. 30, 2023	Jun. 30, 2023	Apr. 19, 2021	Mar. 31, 2021	Feb. 13, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)				162,683	52,762
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)				3,463	4,963
Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)			150,000					250,000
Number of shares available for grant (in shares)	0
Aytu 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award			10 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Aytu 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Aytu 2015 Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)				44,151	38,075
Aytu 2015 Plan | Restricted Stock | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Aytu 2015 Plan | Restricted Stock | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			10 years
Aytu 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years
Neos 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding (in shares)							3,486
Number of shares available for grant (in shares)						5,272
Neos 2015 Plan | Share-Based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award		10 years
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Neos 2015 Plan | Share-Based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Neos 2015 Plan | Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested units outstanding (in shares)							1,786
2023 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of award	10 years
Number of shares available for grant (in shares)	87,129			165,667
Common stock, capital shares reserved for future issuance	200,000
2023 Equity Incentive Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2023 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years
2023 Equity Incentive Plan | Restricted stock awards and restricted stock units | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
2023 Equity Incentive Plan | Restricted stock awards and restricted stock units | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	4 years

Equity Incentive Plans - Stock

Equity Incentive Plans - Stock Options (Details) - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options outstanding, beginning balance (in shares)	52,762
Granted (in shares)	112,000
Forfeited/cancelled (in shares)	(2,045)
Expired (in shares)	(34)
Number of options outstanding, ending balance (in shares)	162,683	52,762
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price outstanding, beginning balance (in dollars per share)	$ 18.37
Granted (in dollars per share)	1.73
Forfeited/cancelled (in dollars per share)	4.78
Expired (in dollars per share)	158.09
Weighted average exercise price outstanding, ending balance (in dollars per share)	$ 6.91	$ 18.37
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life (Year)	9 years 6 months 18 days	9 years 21 days
Number of options exercisable	3,019
Weighted average exercise price exercisable (in dollars per share)	$ 227.16
Weighted average remaining contractual life in years exercisable	5 years 11 months 19 days

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock - Activity (Details)	3 Months Ended
	Sep. 30, 2023 $ / shares shares
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Restricted stock remain unvested during the period end	2,505
Restricted Stock | Aytu 2015 Plan
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares)	38,075
Granted (in shares)	12,500
Vested (in shares)	(6,424)
Unvested outstanding, ending balance (in shares)	44,151
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 142.20
Granted (in dollars per share) | $ / shares	1.77
Vested (in dollars per share) | $ / shares	137.95
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 103.06
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares)	4,963
Vested (in shares)	(561)
Forfeited/Cancelled (in shares)	(939)
Unvested outstanding, ending balance (in shares)	3,463
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 25.62
Vested (in dollars per share) | $ / shares	24.28
Forfeited/Cancelled (in dollars per share) | $ / shares	31.60
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 24.21

Equity Incentive Plans - Rest_2

Equity Incentive Plans - Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Unvested outstanding, beginning balance (in shares) | shares	4,963
Vested (in shares) | shares	(561)
Forfeited/Cancelled (in shares) | shares	(939)
Unvested outstanding, ending balance (in shares) | shares	3,463
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Unvested, weighted average grant date fair value outstanding, beginning balance (in dollars per share) | $ / shares	$ 25.62
Vested | $ / shares	24.28
Forfeited/Cancelled (in dollars per share) | $ / shares	31.60
Unvested, weighted average grant date fair value outstanding, ending balance (in dollars per share) | $ / shares	$ 24.21

Equity Incentive Plans - Unreco

Equity Incentive Plans - Unrecognized Compensation Costs (Details) $ in Millions	3 Months Ended
	Sep. 30, 2023 USD ($)
Unrecognized compensation costs
Unrecognized compensation costs, options	$ 0.3
Unrecognized compensation costs, period for recognition	1 year 8 months 12 days
Restricted Stock | Aytu 2015 Plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 2.8
Unrecognized compensation costs, period for recognition	1 year 9 months 18 days
Restricted Stock | Non-plan
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.3
Unrecognized compensation costs, period for recognition	1 year 3 months 18 days
Restricted Stock Units (RSUs)
Unrecognized compensation costs
Unrecognized compensation costs, excluding options	$ 0.1
Unrecognized compensation costs, period for recognition	1 year 4 months 24 days

Equity Incentive Plans - Stock-

Equity Incentive Plans - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Stock-based compensation expense
Total share-based compensation expense	$ 930	$ 1,177
Cost of Sales
Stock-based compensation expense
Total share-based compensation expense		5
Research and Development Expense
Stock-based compensation expense
Total share-based compensation expense	1	9
Selling and Marketing Expense
Stock-based compensation expense
Total share-based compensation expense		3
General and Administrative Expense
Stock-based compensation expense
Total share-based compensation expense	$ 929	$ 1,160

Warrants - General Information

Warrants - General Information (Details) $ / shares in Units, $ in Millions	Jun. 08, 2023 USD ($) $ / shares shares	Jan. 06, 2023	Aug. 11, 2022 D $ / shares shares	Jan. 26, 2022 $ / shares	Sep. 30, 2022 D	Aug. 31, 2022 $ / shares
Class of Warrant or Right [Line Items]
Stock split, conversion ratio		0.05
Warrants to Purchase Common Stock, Liability Classified, Avenue Capital Warrants, January 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable				Jan. 26, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares				$ 24.20
Warrants to Purchase Common Stock, Liability Classified, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable			Aug. 11, 2022
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 2.32
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)			87,500
Class of warrant or right, number of securities called by each warrant or right (in shares)			1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares			$ 0.02			$ 0.001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, August 2022
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)			1,265,547
Class of warrant or right, number of securities called by each warrant or right (in shares)			1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 3.30		$ 8.60
Warrants and rights outstanding, term			5 years
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, 20 consecutive trading day period preceding 16th trading day, lowest trading days (in days) | D			5		5
Class of warrant or right, exercise price adjustment, quotient, divisor, common stock, volume-weighted average price, consecutive trading days preceding 16th trading day (in days) | D			20		20
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario one			5
Class of warrant or right, exercise price adjustment, quotient, dividend, scenario two (in dollars per share) | $ / shares			$ 2.32
Class of warrant or right, exercise price adjustment, maximum shares (in shares)			2,325,581
Class of warrant or right, exercise price adjustment, equity offering, common stock price lower than warrant exercise price prior to 2nd anniversary of Stock Combination Event, adjusted exercise price (in dollars per share) | $ / shares			$ 2.32
Warrants to Purchase Common Stock, Liability Classified, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Issuance of common stock, net of issuance costs (in shares)	1,743,695
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 0.0001
Warrants to Purchase Common Stock, Liability Classified, Pre-funded Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	430,217
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 0.0001
Warrants to Purchase Common Stock, Liability Classified, Common Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, date from which warrants or rights exercisable	Jun. 08, 2023
Class of warrant or right, number of securities called by each warrant or right (in shares)	1
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 0.0001
Warrants to Purchase Common Stock, Liability Classified, Tranche A Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Class of warrant or right, exercise price of warrants or rights (in dollars per share) | $ / shares	$ 3.18
Warrants and rights outstanding, term	5 years
Class of warrant, term of expiration after closing price of common stock	30 days
Class of warrant or right, percentage of exercise price equaling common stock	200%
Warrants to Purchase Common Stock, Liability Classified, Tranche B Warrants, June 2023
Class of Warrant or Right [Line Items]
Class of warrant or right, number of securities called by warrants or right (in shares)	2,173,912
Warrants and rights outstanding, term	5 years
Class of warrant or right, expiration term on achievement of consolidated trailing Twelve-Month adjusted EBITDA	30 days
Adjusted earnings before interest, taxes, depreciation, and amortization | $	$ 12

Warrants - Warrants Activity (D

Warrants - Warrants Activity (Details) - Warrants to Purchase Common Stock - $ / shares	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023
Class of Warrant or Right [Line Items]
Outstanding, number of warrants (in shares)	6,538,052
Outstanding, number of warrants (in shares)	6,538,052	6,538,052
Outstanding, weighted average remaining contractual life	4 years 5 months 15 days	4 years 8 months 15 days
Weighted Average
Class of Warrant or Right [Line Items]
Outstanding, exercise price (in dollars per share)	$ 4.42
Outstanding, exercise price (in dollars per share)	$ 4.42	$ 4.42

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	6,750,854	1,784,184
Warrants to Purchase Common Stock, Liability Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	6,498,980	1,642,235
Warrants to Purchase Common Stock, Equity Classified
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	39,072	56,486
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	162,683	3,799
Employee Unvested Restricted Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	46,656	73,164
Employee Unvested Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	3,463	8,500

License Agreements (Details)

License Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2017	Feb. 29, 2016
Settlement Agreement and Associated License Agreement, 2014, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum		$ 1
License Agreement, 2017, Shire LLC, New Drug Application
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement, up-front, non-refundable license fee paid, maximum	$ 1

Segment Reporting - General Inf

Segment Reporting - General Information (Details) - segment	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Number of reportable segments	2	2

Segment Reporting - Select Fina

Segment Reporting - Select Financial Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Revenues [Abstract]
Revenue from contract with customer	$ 22,099	$ 27,655
Loss from operations	(1,504)	(1,808)
Depreciation and amortization	1,941	1,855
Stock-based compensation expense	930	1,177
Rx
Revenues [Abstract]
Revenue from contract with customer	17,817	18,652
Loss from operations	(866)	(993)
Depreciation and amortization	1,554	1,574
Stock-based compensation expense	725	1,162
Consumer Health Segment
Revenues [Abstract]
Revenue from contract with customer	4,282	9,003
Loss from operations	(638)	(815)
Depreciation and amortization	387	281
Stock-based compensation expense	$ 205	$ 15